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 Omega-3 fatty acids, particularly docosahexaenoic (DHA) and eicospentaenoic acid 
(EPA), are important mediators for cardiovascular disease, fetal/infant development, 
neurological disorders and inflammatory diseases.  Supplementation and washout studies are 
important for future research on the physiological effects of omega-3 fatty acids and for 
determination of the proper washout period for future cross-over studies.  In this study, 
omega-3 fatty acid blood biomarker comparisons are made for the n-3 HUFA score (% of n-3 
HUFAs in total HUFAs) and omega-3 index (sum of EPA + DHA) in plasma, erythrocytes, 
whole blood and a novel finger-tip prick blood method (FTPB) of analysis.  This FTPB 
method of fatty acid analysis is further tested to determine the potential for its use in fatty 
acid analysis.  In addition, gender differences in response to omega-3 fish oil 
supplementation are analyzed in all four blood fractions. 
Nine males and seven females were supplemented with 8 fish-oil capsules per day 
(providing 3.2 g/day EPA and 1.6 g/day DHA) for four weeks, followed by an eight-week 
omega-3 washout period.  Venous plasma, erythrocyte and whole blood samples were 
collected during weeks 0, 4, 8 and 12 and FTPB samples were collected weekly during 
supplementation and washout fatty acid analysis was performed.   
EPA and DHA incorporation is lowest in magnitude in erythrocytes relative to all 
other blood fractions.  Omega-3 blood biomarker comparisons demonstrate that the n-3 
HUFA score is a more reliable measure across all blood fractions compared to the omega-3 
index.  In addition, the n-3 HUFA score demonstrates no differences (p > 0.05) between 
FTPB and whole blood analysis, providing evidence to support its usefulness as a tool for 
fatty acid analysis.  However, differences (p < 0.05) do exist between these methods for 
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saturated fatty acid, monounsaturated fatty acids, omega-6 polyunsaturated fatty acids 
(PUFAs) and omega-3 PUFAs.  Baseline fatty acid levels for DHA, and the DHA:EPA and 
DHA:DPA ratios tend to be higher (p < 0.05) in females, and docosapentaenoic acid n-3 
(DPAn-3) is higher (p > 0.05) in males across all blood fractions.  Furthermore, a gender 
effect (p < 0.05) is seen for the DHA:EPA ratio across all blood fractions.  At baseline, 
female DHA:EPA is higher (p < 0.05) than males with supplementation lowering both male 
and female values and removing any differences (p > 0.05) between genders.  Washout 
results in a return of levels towards baseline, however, baseline levels are not fully reached.  
Furthermore, while gender differences do begin to reform during washout, these differences 
are not significant (p > 0.05).   
In conclusion, omega-3 fatty acid responses, particularly DHA:EPA ratio, 
demonstrate significant gender differences that may be related to differences in long-chain 
PUFA synthesis pathways between males and females. In addition, the n-3 HUFA score may 
be a more valuable omega-3 blood biomarker than the omega-3 index, as the n-3 HUFA 
score displays more consistent levels across all blood fractions.  Finally, the FTPB method of 
analysis may be a useful tool in the measurement of fatty acid composition, however, some 
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1.1 Omega-3 Fatty Acid Consumption and Health Benefits 
Dietary intake of omega-3 fatty acids have been associated with various health 
benefits including, a reduction in cardiovascular disease (CVD) risk, optimal infant 
neurological and visual development, and moderation of a variety of inflammatory 
diseases (Moyad, 2005a; Moyad, 2005b).  As such, omega-3 fatty acids, particularly 
eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3), in 
blood as a biomarker of omega-3 fatty acid intake have been proposed as a modifiable 
risk factor for cardiovascular disease (Harris and Von Schacky, 2004).  In blood, there 
are several components and lipid classes that could be analyzed for EPA + DHA content 
to serve as potential biomarkers.  Cost of these analyses is a significant consideration for 
large-scale studies and clinical screening.  There is little information directly comparing 
various blood components with omega-3 fatty acid supplementation and washout.  In 
addition, the research completed has been done so in males only.  There is evidence 
demonstrating that females have a higher rate of biosynthesis of longer chain omega-3 
fatty acids from dietary precursors than males (Burdge and Wootton, 2002; Burdge, Jones, 
and Wootton, 2002; Pawlosky et al., 2003a).  For these reasons, studies examining the 
potential use of omega-3 fatty acids as biomarkers for health and disease requires the 
inclusion of both male and female participants. 
The American Heart Association has recommended an intake of 500 mg of EPA 
and DHA per day to reduce the general risk of CVD (Gebauer et al., 2006).  Recently, it 
has been suggested that 750 mg/d will reduce the risk of arrhythmias and sudden cardiac 
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death (SCD), while even greater intakes may provide further CVD risk reduction through 
an inverse linear relationship between intake and reduced circulating plasma 
triacyglycerol (TAG) levels (Mozaffarian and Rimm, 2006; Mozaffarian, 2007).  Dietary 
intake of EPA and DHA varies greatly across countries (Table 1).  Societies with a 
higher proportion of seafood consumption such as the Greenland Inuit and the Japanese 
have significantly higher intakes than North Americans.  Populations consuming high 
levels of seafood have much lower rates of ischemic heart disease, and higher blood 
levels of EPA + DHA are associated with decreased coronary heart disease rates (Lands, 
2005).  Estimates of death rates from coronary heart disease (CHD) in these populations 
have been placed at 3.9%, 5.5%, 11.2% and 13.0% in female Greenlanders, Japanese, 
Canadians and Americans, respectively (World Health Organization, 1995; American 
Heart Association, 2005). 
 
Table 1. Omega-3 HUFA Intakes for Canadian, American, Japanese and Greenlanders 
 Canada1 American2 Japan3 Greenland4 
 mg/d 
EPA 35 28 337 5290 
DHA 82 65 599 6785 
Total  n-3 HUFA 143 93 1032 15065 
EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; HUFA, highly unsaturated 
fatty acids (≥20 carbons, ≥ 3 double bonds). 1(Denomme, Stark, and Holub, 2005), 
2(Stark et al., 2005), 3(Kuriki et al., 2003), 4(Bang, Dyerberg, and Hjoorne, 1976). 
 
 
1.1.1 Cardiovascular Disease 
In early studies it was discovered that individuals given advice to increase their 
fatty fish intake displayed a 29% reduction in all-cause mortality after two years (Burr et 
al., 1989).  At this time, conclusions were being drawn linking an increase in fish intake 
and therefore an increase in polyunsaturated fatty acid (PUFA) intake to a reduction in 
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risk for CVD and mortality (Leaf and Weber, 1988).  EPA and DHA were not directly 
implicated in these improvements in CVD and mortality until it was shown that fish oil 
supplements (high in EPA and DHA specifically) reduced the risk of death, nonfatal 
myocardial infarction (MI) and nonfatal stroke by 15% with a 20% reduction in CVD 
(GISSI-Prevenzione Investigators, 1999).  Secondarily, a 20% reduction in all-cause 
mortality and a 45% reduction in SCD were observed.  Supplementation with fish oil 
results in rapid incorporation of EPA and especially DHA into the human heart 
membranes (Metcalf et al., 2007), which is thought to be related to the aforementioned 
improvements in heart health. 
SCD claims the life of approximately 460 000 individuals in the U.S. each year 
and accounts for greater than half of all deaths due to CHD (Rosenbaum, 2007).  SCD 
occurs within minutes after the initial symptoms appear, and involves an abrupt loss of 
cardiac function due to either an abnormal heart rate (ventricular tachycardia or 
ventricular fibrillation) or an irregular rhythm (arrhythmia) where the heart stops beating.  
An anti-arrhythmic effect of EPA and DHA has been demonstrated in cultured neonatal 
rat cardiomyocytes (Kang and Leaf, 1994), animal models (Leaf et al., 1999) and in 
clinical populations (Leaf et al., 2005).  Furthermore, omega-3 fatty acids reduce resting 
heart rate that may indicate a role in altering vagal tone, as well as improvements in left 
ventricular diastolic filling (Mozaffarian et al., 2005).  The anti-arrhythmic mechanism of 
EPA and DHA has not been fully elucidated, although direct or indirect interaction of 
omega-3 PUFAs with membrane proteins such as Na+ (Goel, Maddaford, and Pierce, 
2002) and Ca2+ ion channels (Honen, Saint, and Laver, 2003; Swan et al., 2003) have 
been proposed.  Furthermore, omega-3 fatty acids can alter membrane fluidity of cell 
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membranes, thereby possibly altering the function of transmembrane proteins and their 
interaction with specific ligands (Ma et al., 2004). 
In addition to direct effects on heart tissue, increased omega-3 fatty acid intake 
reduces the risk of CVD by other mechanisms including; a less inflammatory eicosanoid 
profile, suppressed hepatic very low-density lipoprotein (VLDL) production resulting in 
lower circulating TAG, improved clearance of chylomicrons and an increase in high-
density lipoprotein (HDL) in the blood stream (Mozaffarian et al., 2005).  The reduction 
in inflammatory mediators is likely the explanation for the stabilization of arterial plaques, 
and the mild reduction of blood pressure may be attributable to an improvement in 
endothelial function (Harris, 2007). 
 
1.1.2 Fetal/Infant Development 
Maternal long chain fatty acids (LCFA), particularly arachidonic acid (AA, 20:4n-
6) and DHA, are found in high concentrations in the fetal brain. Maternal intake of these 
fatty acids may improve neurological function during fetal development and may be 
essential in fetal life (Crawford, 1993).  For this reason it has been hypothesized that 
females have an upregulated biosynthesis of DHA from its precursors (Stark et al., 2005) 
to adequately supply the potential demand by a fetus for these omega-3 fatty acids 
(Clandinin et al., 1980).  This upregulation is thought to be related to, and possibly be the 
result of the increase in estrogen levels in females during pregnancy (Giltay et al., 2004).   
DHA and/or LCFA (PUFA, i.e. AA) supplementation in pregnant women is 
linked to improvements in mental development, long-term cognition and visual 
development of infants (Eilander et al., 2007).  Furthermore, neurologically abnormal 
infants tend to have significantly lower umbilical cord DHA composition at birth (Dijck-
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Brouwer et al., 2005), where children from mothers who received cod liver oil during 
pregnancy have higher IQs at the age of 4 compared to children of mother’s who did not 
receive cod liver oil (Helland et al., 2003).  The evidence indicates that early postnatal 
neurological capabilities in infants are negatively affected by low fetal AA and DHA 
fatty acid status. 
Premature infants are likely to be more susceptible to DHA deficiencies due to 
inadequate intrauterine DHA supply of the fatty acids (Helland et al., 1998).  The need 
for DHA and AA for proper neurological development, however, does not end at child 
birth.  The brain “growth spurt” beginning in the last trimester of pregnancy continues 
into the first few postnatal months (Clandinin et al., 1980).  As mentioned previously, 
maternal DHA and AA in the diet is important for fetal brain growth, but it continues to 
be important for infants to obtain these fatty acids from breast milk.   
EPA and DHA intake is variable in pregnant Canadians with 20% of pregnant 
women not consuming detectable levels of DHA (Denomme, Stark, and Holub, 2005).  
The concentrations of DHA and AA in a mother’s milk is also variable and dependent on 
the maternal diet (Harris, Connor, and Lindsey, 1984; Helland et al., 1998; Innis and 
Kuhnlein, 1988). For this reason, screening of mothers and infants at birth may be an 
important tool to provide the infant with a decreased risk for chronic disease later in life. 
 
1.1.3 Inflammatory Disease and Other Health Benefits 
Increased omega-3 fatty acid consumption and tissue accumulation have 
significant impacts on inflammation through eicosanoid (Kapoor and Huang, 2006) and 
docosanoid pathways (Serhan, 2006).  EPA and DHA compete with AA for the sn-2 
position on phospholipid membranes.  These fatty acids are released from the membrane 
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by the enzyme phospholipase A2 and serve as substrates for various inflammatory related 
enzymes including cyclooxygenase (COX), lipoxygenase (LOX) and for docosanoids 
COX-2 (Chen et al., 2001).  Furthermore, EPA competitively inhibits the oxygenation of 
AA by COX (Obata et al., 1999).  This in turn decreases the capacity of cells to 
synthesize COX- and LOX-derived eicosanoids from AA (Lee et al., 1985; Sperling et al., 
1993).   
Omega-3 derived eicosanoids tend to be less inflammatory than n-6 derived 
eicosonoids (Calder and Burge, 2004).  Docosanoids, particularly those derived from 
DHA such as docosatriene, appear to be protective against leukocyte infiltration while 
they also demonstrate a down-regulation of inflammatory cytokines (Hong et al., 2003).  
Other benefits of omega-3 fatty acids have been demonstrated in inflammatory diseases 
such as rheumatoid arthritis (Cleland, James, and Proudman, 2003; Covington, 2004; 
James, Proudman, and Cleland, 2003; Volker et al., 2000), inflammatory bowel diseases 
(Belluzzi et al., 1996; Belluzzi, 2002), ulcerative colitis (Nieto et al., 1998), osteoarthritis 
(Curtis et al., 2002), hepatitis (Leu, Lin, and Hsu, 2004) and asthma (Mickleborough et 
al., 2003). 
Omega-3 fatty acids have also been linked to improvements in some neurological 
disorders.  Individuals with Alzheimer’s disease have lower DHA levels than individuals 
without the disease (Tully et al., 2003).  Omega-3 fatty acids have also shown promise 
with alleviating depression and schizophrenia (Mamalakis et al., 2004; Peet, 2003; Su et 
al., 2003).  Omega-3 fatty acids have the ability to reduce AA and other cytokines such as 
interleukin-1, 2 and 6, interferon-gamma and interferon-alpha that play major roles in 
these conditions (Mamalakis et al., 2004; Peet, 2003).  Specifically, DHA-derived 
docosanoids such as neuroprotectin D1 (or docosatriene) appear to elicit very strong 
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counter-regulatory actions on molecular signaling following oxidative stress-induced 
brain ischemia-reperfusion and neural cell damage.  The neuroprotective properties of 
DHA are presumably, in part, due to reduced AA incorporation into tissue and thus a 
reduction in the pro-inflammatory AA-derived eicosanoid synthesis (Bazan, 2006). 
Omega-3 fatty acids may also mediate or improve various medical conditions 
such as osteoporosis (Sun et al., 2004), and a number of different cancers including breast 
cancer (Rose and Connolly, 1993; Rose et al., 1995), colorectal cancer (Hofmanova, 
Vaculova, and Kozubik, 2005), endometrial cancer (Terry et al., 2002), leukemia (Miura 
et al., 2004), melanoma (Albino et al., 2000; Liu et al., 2001), ovarian cancer (Bosetti et 
al., 2001; La Vecchia et al., 1987), pancreatic cancer (Merendino et al., 2003), prostate 
cancer (Connolly, Coleman, and Rose, 1997; Rose and Connolly, 1991) and renal cell 
cancer (McCabe et al., 2005). One hypothesis for the mechanism of action in cancer 
prevention is thought to be related to the inhibition of the activities of the COX and LOX 
enzymes involved in the eicosanoid pathway (Rose and Connolly, 2000). 
 
1.2 Gender and Omega-3 Fatty Acid Metabolism 
There is growing evidence for upregulated biosynthesis of longer chain omega-3 
fatty acids, particularly DHA, in women compared to men (Burdge and Wootton, 2002; 
Pawlosky et al., 2003a).  This is thought to be an adaptation to accommodate the high 
fetal demand for DHA during the third trimester of pregnancy and the fetal brain growth 
spurt (Clandinin et al., 1980).  Evidence regarding DHA biosynthesis from alpha-
linolenic acid (ALA, 18:3n-3) using stable isotopes indicates that biosynthesis may be 
higher in women than in men, in particular during the conversion of 22:5n-3 to DHA 
when dietary EPA and DHA intake is low (Burdge and Wootton, 2002; Pawlosky et al., 
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2003a).  DHA status has been shown to be increased during pregnancy (Stark et al., 
2005) and altered with hormone replacement therapy (Stark, Park, and Holub, 2003) and 
with hormonal therapy in transsexuals (Giltay et al., 2004), with levels of DHA being 
higher in these conditions.  Estrogen may upregulate DHA biosynthesis and/or 
mobilization of DHA into blood.  Estrogen has been demonstrated to increase 
peroxisomal activation, which is directly implicated in DHA biosynthesis and oxidation 
(Jeong and Yoon, 2007) 
In summary, omega-3 fatty acids such as those obtained from fish oil capsules are 
associated with improvements and/or prevention of a number of heath risks and disease.  
These include but are not limited to cardiovascular disease, fetal development, 
inflammatory diseases and cancer.  To properly understand how omega-3 fatty acids 
mediate such conditions it is important to understand basic nomenclature and lipid 
absorption, transport and incorporation into tissues following ingestion of meals that are 





2.1 Fatty Acid Nomenclature 
The standard nomenclature of fatty acids is determined by three factors: 1) the 
number of carbons in the chain, 2) the number of double bonds in the carbon chain and 3) 
the location of the first double bond relative to the methyl end in the carbon chain.  Fatty 
acid nomenclature is complicated by the lack of adherence to s single systematic system, 
but practical nomenclature tends to be a mixture of trivial and systematic names (IUPAC-
IUB Commission on Biochemical Nomenclature, 1978) with the actual usage varying 
between various disciplines such as chemistry and biology.  A bioinformatic amenable, 
classification and nomenclature system for lipids has been recently developed (Fahy et al., 
2005), however, acceptance of this system has not been immediate.  
Biological fatty acids generally exist with an even number of carbons in the chain, 
although odd-chain fatty acids of bacterial origin are present.  In mammals, fatty acids in 
the range of 10 to 24 carbons tend to dominate structural lipids.  Furthermore they tend to 
be located in structures such as phospholipids, TAGs, and cholesteryl esters.  Fatty acids 
on phospholipids tend to be localized in the sn-1 and sn-2 position of the glycerol 
backbone with the phosphate group in the sn-3 position.  In TAGs, three fatty acids are 
esterified to a glycerol backbone.  A single fatty acid can also be esterified to a hydroxyl 
group of cholesterol to form cholesteryl esters. There is also a small circulating pool of 
non-esterified fatty acids (NEFAs) that may or may not be associated with albumin. 
Saturated fatty acids (SFAs) do not contain carbon-carbon double bonds.  Two of 
the most common SFAs in humans are palmitic acid (16:0, where 16 represents the 16 
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chain carbon and the 0 represents the number of carbon-carbon double bonds) and stearic 
acid (18:0).  Monounsaturated fatty acids (MUFAs) represent the fatty acids containing 
one carbon-carbon double bond in the carbon chain.  The most common MUFA in 
humans is oleic acid (OA, 18:1n-9; 18 carbons, 1 carbon-carbon double bond with n-9 
denoting the double bond is located 9 carbons from the methyl end).  SFAs and MUFAs 
are the dominant fatty acids in TAGs and tend to be found in the sn-1 position of 
phospholipids.  PUFAs include any fatty acid with 2 or more carbon-carbon double bonds.  
Linoleic acid (LA, 18:2n-6) is a common PUFA found in many tissues in humans.  
Highly unsaturated fatty acids (HUFAs) are defined as any fatty acid containing 20 or 
more carbons and 3 or more carbon-carbon double bonds.  HUFAs have important 
structural and cell-signaling roles not attributable to all PUFAs.  For example HUFAs are 
mainly located in the sn-2 position of phospholipids and are active in eicosanoid 
pathways.  The most common found omega-6 HUFA in human tissue is AA.  Two of the 




Figure 1: Omega-3 Highly Unsaturated Fatty Acid Structures. A. Eicosapentaenoic Acid, 
EPA, 20:5n-3. B. Docosahexaenoic Acid, DHA, 22:6n-3. 
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2.2 Fat Digestion and Absorption 
The majority of consumed fat is in the form of TAGs, which need to be 
hydrolyzed before they are ready for absorption in the small intestine.  The major 
digestion of TAGs occurs through the action of pancreatic lipase.  Dietary phospholipids 
and cholesterol esters comprise a much smaller portion of diet in humans and are 
hydrolyzed by phospholipases and cholesteryl esterases, respectively (Calder and Burge, 
2004).  Pancreatic lipase hydrolyzes NEFA from TAGs, resulting in a mixture of 
monoacylglycerols, glycerols and NEFAs that can be absorbed by the enterocyte.  
Following absorption of the lipids into the enterocytes, the NEFAs are reassembled/re-
esterified inside the endoplasmic reticulum to form cholesteryl esters, TAGs and 
phosphatidylcholine (PC).  NEFAs with more than 10 to 12 carbons in the chain are 
activated through coupling to coenzyme-A (CoA) and are subsequently repackaged to 
form TAGs, PC and cholesteryl esters.  Fatty acids are re-esterified onto the 
monacylglycerols to form TAGs to be incorporated into chylomicrons.  The chylomicron 
is then transported to the cell membrane and exocytosed in the lymphatic system where it 
can bypass the liver when it enters the blood stream (Gropper, Smith, and Groff, 2005).  
Short chain NEFAs, however, are directly entered into the portal blood and sent to the 
liver without undergoing any reformation (Calder and Burge, 2004).   
 
2.3 Fat Transport 
Chylomicrons are the most important postprandial lipoprotein for transport of 
dietary (exogenous) TAGs.  Other endogenous lipoproteins exist to support different 
metabolic functions.  Lipoproteins are characterized in a number of different ways 
including: lipid to protein ratio, proportions of TAG, esterified and non-esterified 
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cholesterol and phospholipids.  The common lipoprotein classification scheme is based 
on density (Table 2).  In order from lowest density to highest the lipoproteins are 
identified as follows: chylomicrons, VLDLs, intermediate density lipoproteins (IDL), low 
density lipoproteins (LDL) and HDLs. 
 
Table 2. Characteristics of Major Classes of Plasma Lipoproteins in Humans 
    Composition (g/100g) 




Apolipoproteins Protein TAG Cholesterol PL 
Chylomicrons <0.95 80 - 1000 A1, A2, B48,  C1-3, E 2 82 9 7 
VLDL 0.95 - 1.01  30 - 80 B100, C1-3, E 8 52 22 18 
IDL 1.01 - 1.02 25 - 30 B100, C1-3, E 15 20 35 20 
LDL 1.02 - 1.06 20 - 25 B100 21 9 47 23 
HDL 1.06 - 1.21 5 - 15 A1, A2, C1-3, E 50 3 19 28 
Adapted from (Calder and Burge, 2004) and (Gropper, Smith, and Groff, 2005). VLDL, 
very low density lipoprotein; IDL, intermediate density lipoprotein; LDL, low density 
lipoprotein; HDL, high density lipoprotein; TAG, triacylglycerol; PL, phospholipid. 
 
 
Upon entry of lipids into the blood stream for circulation, they undergo a number 
of different packaging steps (Figure 2).  When chylomicrons enter the blood stream they 
bind to lipoprotein lipase (LPL) located on the endothelial surface of the capillaries, 
primarily in adipose tissue.  LPL then catalyses the hydrolysis of fatty acids from the 
TAGs in the chylomicron (Frayn, 2003).  The resultant NEFAs are then used for storage 
inside the tissue.  The leftover particle has less TAGs and is enriched in cholesteryl esters 
and is known as a chylomicron remnant (Calder and Burge, 2004).  Chylomicron 
remnants are not identifiable by LPL and are removed from the blood stream by liver 
endocytosis.  The resultant VLDL is less TAG-rich in composition and undergoes further 
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TAG “stripping” at extracellular endothelial sites, once again resulting in an even less 
TAG-rich particle or IDL (Gropper, Smith, and Groff, 2005).  Hepatic lipase from the 
liver further degrades IDL to form the cholesterol-rich LDL, which is principally 
removed from the blood stream at extra-hepatic peripheral tissue sites.  LDLs carry 
approximately 60% of total serum cholesterol (Frayn, 2003).  
 
Figure 2. Lipid and Lipoprotein Metabolism Pathways. VLDL, very low-density 
lipoprotein. IDL, intermediate-density lipoprotein. LDL, low-density lipoprotein. HDL, 
high-density lipoprotein. NEFA, non-esterified fatty acid. LPL, lipoprotein lipase. HL, 
hepatic lipase. CETP, cholesterol ester transfer protein. 
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The role of LDLs is to transport cholesterol to tissues where it is taken up and 
used for membrane construction or in the construction of other metabolites such as 
steroid hormones.  LDL interacts with the LDL receptors on the tissues to remove the 
LDL from circulation.  The LDL/LDL receptor complex is internalized, and the LDL 
receptor is returned to the cell membrane following dissociation from the LDL particle.  
The LDL particle is degraded by lysozomal enzymes yielding amino acids, NEFAs and 
free cholesterol (Gropper, Smith, and Groff, 2005).   
The chylomicron remnant, which the liver takes up early in this process is 
degraded, repackaged and released into the hepatic veins not only as VLDL (as 
mentioned earlier), but also as HDLs.  HDLs can also be synthesized in the enterocyte 
and released into circulation (Frayn, 2003).  HDLs provide positive health benefits as 
they function to remove any non-esterified cholesterol from cells and other lipoproteins 
where it has accumulated and transport it back to the liver where it is excreted in bile 
(Frayn, 2003).  Lipoprotein levels are not equal between men and women of reproductive 
age, with women generally displaying lower LDL and higher HDL plasma compositions 
(Connelly et al., 1992).  
 
2.4 Metabolic Fate of Fat  
In general, fatty acids are stored in adipose tissue as TAGs, and are hydrolyzed 
through the action of hormone-sensitive lipase (HSL) (Frayn, 2003).  Insulin stimulates 
LPL to release fatty acids from circulating lipoproteins for storage in adipose and other 
tissues as TAGs.  Glucagon during fasting and adrenaline and noradrenaline during 
exercise stimulates HSL to mobilize NEFAs into the blood stream from adipose for 
delivery to tissues for mitochondrial β-oxidation (Frayn, 2003). 
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2.5 Long-chain Omega-3 Fatty Acid Metabolism 
Very long chain fatty acid (VLCFA) have important structural and cell signaling 
roles in mammalian systems.  Biosynthetic pathways are present for the utilization of 
VLCFAs and these are not primarily oxidized for energy.  The metabolic pathways for 
the biosynthesis of VLCFA, however, require dietary sources of the fatty acid precursors 
LA and ALA.  LA and ALA are primarily synthesized by plants as mammals lack Δ12 
and Δ15 desaturase activities for the generation of carbon-carbon double bonds.  
Mammals are capable of double bond insertions and chain elongations of the 18 carbon 
PUFAs to 22 carbon PUFAs such as DHA.  The placement of a double bond at the Δ4 
position is particularly complicated as it relies on elongation, Δ6 desaturation and then β-
oxidation in the peroxisome (Sprecher et al., 1995; Su et al., 2001) (Figure 3).  DHA 
synthesis has been demonstrated to be low in humans (Pawlosky et al., 2003b), and 18 
carbon chains are for the most part oxidized (McCloy et al., 2004).   
VLCFAs can not directly enter the mitochondria, but must be shortened to 18-
carbon fatty acids by peroxisomal β-oxidation before entering mitochondrial β-oxidation 
(Reddy and Hashimoto, 2001).  This selectivity is largely mediated by VLCFA-CoA 
synthetases specific to the peroxisomal membrane for the activation of VLCFAs 
(Hashimoto, 1999).  Disruptions in VLCFA handling leads to LCFA accumulation and 
potential toxicity which manifest in diseases such as Zellwegers syndrome and 
adrenoleukodystrophy (Wanders, 2004).  In addition, perioxisomal β-oxidation is not 
energy efficient due to the lack of oxidative phosphorylation in the peroxisome, 
suggesting that this oxidative capacity is largely for maintenance of VLCFA levels for 
structural incorporation.  Thus, the peroxisome is an important factor in the metabolism 
of DHA with both synthesis and oxidation occurring in the organelle.  
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Figure 3. Biosynthesis of Polyunsaturated Fatty Acids from Fatty Acid Precursors 
 
The peroxisomal β-oxidation system is inducible by a number of different agents, 
including high-fat diets and fibrates (Berthou et al., 1995).  It has been further proposed 
that these fibrates and other peroxisomal proliferators increase gene activity for 
peroxisomal β-oxidation enzymes through the action of peroxisome proliferator-activator 
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receptors (PPARs).  Estrogen has been demonstrated to affect PPARs and the peroxisome 
(Jeong and Yoon, 2007).  In addition to a potential estrogenic effect on DHA biosynthesis, 
estrogen has been associated with increased 16:0 and decreased 18:0, 22:0, 24:0 and 
24:1n-9 (Stark, Park, and Holub, 2003).  The mechanisms behind estrogenic effects on 
differences in fatty acid concentrations are largely speculative (Stark, Park, and Holub, 
2003). 
 
2.6 Eicosapentaenoic Acid and Docosahexaenoic Acid in Tissues 
EPA and DHA can be incorporated into various lipid classes and membranes.  
The lipid classes present in a tissue or blood component contribute to the amount of EPA 
and DHA in a tissue.  Phosphatidylcholine (PC) tends to be the dominant fatty acid 
containing lipid in most tissues.  Triacylglycerols, however, can be the dominant lipid in 
certain tissues including adipose and plasma (more so in postprandial plasma than fasting 
plasma).  Plasma and erythrocytes are candidates for use as blood biomarkers for omega-
3 fatty acid intake.  These blood components do differ in lipid class composition (Table 
3).  Plasma contains significant amounts of cholesteryl esters, triacylglycerols and PC.  
Erythrocytes are mainly PC, phosphatidylethanolamine (PE) and unesterified cholesterol 
(unesterified cholesterol does not contribute to the fatty acid composition).  It has been 
suggested that erythrocytes reflect longer-term intake of omega-3 fatty acids over the 
lifespan of the erythrocyte, which has a half-life of approximately 120 days (Arab, 2003).  
However, a doubling of EPA levels in erythrocytes has been shown after only 3 days of 
supplementation (Katan et al., 1997), and EPA has been observed to increase in 
erythrocyte phospholipids by day 2 of fish oil supplementation (Skeaff and Duffield, 
1998), suggesting fatty acid incorporation into erythrocyte membranes is not dependent 
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Table 3. Lipid Class Composition of Tissues 
Lipid Class Tissue 
 Heart Liver Erythrocyte Plasma 
 Relative % of total lipid 
Cholesteryl esters trace 2 - 16 
Triacylglycerols 4 7 - 49 
Cholesterol 4 5 30 6 
Diacylglycerols 1 - trace trace 
Non-esterified fatty acids - trace - 2 
Diphosphatidyl glycerol 12 5 - - 
Phosphatidyl ethanolamine 33 20 21 - 
Phosphatidyl inositol 4 4 3 - 
Phosphatidyl serine - - 3 - 
Phosphatidyl choline 39 55 32 24 
Sphingomyelin 2 2 8 2 
Lysophosphatidyl choline - - 1 1 
Adapted from (Christie, 1985) 
 
on erythropoiesis and that fatty acid exchange with the plasma environment occurs. 
EPA has been demonstrated to rapidly incorporate into PC and PE (Galloway et 
al., 1985) with the highest amount of EPA incorporating into the fatty acyl PC (Holub, 
Celi, and Skeaff, 1988).  PC has a larger polar head group and tend to be found on the 
outer bilayer and spin-labeled phospholipid analysis indicate transbilayer movement of 
PC into the interior is a slow process (Rousselet et al., 1976; Seigneuret and Devaux, 
1984; van Meer and Op den Kamp, 1982).  Therefore the majority of EPA remains on the 
outer bilayer and is readily available for transfer particularly from plasma to tissue outer 
membranes and vice-versa. 
Conversely, DHA is primarily located in phosphatidyl ethanolamine (PE) and it 
was determined that phosphatidyl serine (PS) and PE move at much faster rate to the 
inner bilayer, relative to PC (Seigneuret and Devaux, 1984).  This movement across the 
bilayer is more time consuming than PC incorporation into the outer bilayer.  The 
presence of an ATP-dependent transport mechanism for both PS and PE, and an ATP-
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independent mechanism for the much slower transbilayer movement of PC has been 
proposed (Seigneuret and Devaux, 1984).  Furthermore, the outward movement of lipids 
in the membrane is much slower (t1/2 ~ 1.5 hours) than the inward movement (t1/2 ~ 5-
10 minutes) with the continuous and slow outward movement completely independent of 




Rationale and Objectives 
 
3.1 Rationale 
3.1.1 Blood Biomarkers of Omega-3 Fatty Acids 
A number of criteria need to be met for a biomarker to be considered a risk factor 
for health and disease.  These criteria include consistency of the epidemiological data 
(between populations, within populations and prospective cohorts), a strong association 
between the biomarker and disease, independence between the biomarker and disease, 
biological plausibility, modifiability, risk reduction with modification and the presence of 
a standardized measure (biological variability, analytical reproducibility) (Table 4).  In 
the case of omega-3 fatty acids there are several analytical options including blood 
fractions (erythrocytes, plasma/serum or whole blood) and lipid classes (phospholipids, 
cholesteryl esters, triacylglycerols) resulting in a lack of a consensus on a standardized 
measure.  There is considerable interest in identifying a standard measure to allow large-
scale epidemiological studies on omega-3 fatty acids to proceed. 
Adipose tissue is often believed to be the gold standard for reflecting long-term 
fatty acid intake, however, adipose biopsies are not suitable for large-scale clinical 
screening.  The sum of EPA + DHA composition in erythrocytes (Omega-3 Index) has 
been proposed as a useful omega-3 biomarker in humans (Harris and Von Schacky, 2004).  
A higher than 8% erythrocyte EPA + DHA was determined to provide health benefits 
while less than 4% was considered detrimental to health.  On the other hand, plasma 
phospholipid EPA + DHA has also been used as a measure of fatty acid intake following 
fish oil supplementation (Prisco et al., 1996) and appears to reflect omega-3 intake from 
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fish oil supplementation.  Other biomarkers of omega-3 fatty acid intake that may be 
useful include the EPA/AA ratio (Rupp et al., 2004), the omega-6/omega-3 ratio (Harris, 
2006) and n-3 HUFA status, specifically n-3 HUFAs in total HUFA composition (n-3 
HUFA score) (Stark et al., 2005).  Recently, across 30 dietary fatty acids, erythrocyte 
fatty acid composition was shown to correlate more strongly with fatty acid intake than 
did plasma (Sun et al., 2007). 
 
Table 4. The Omega-3 Index as a Risk Factor for Disease 
Biomarker Guideline Evaluation
Consistency of Epidemiological Data  
  Between Populations Yes 
  Within Populations Yes 
  Prospective Cohorts Yes 
Strong Association Between Biomarker and Disease Yes 
Independence from Other Known Risk Factor  Yes 
Biological Plausibility Yes 
Modifiable (Safely, Quickly, and Cheaply)  Yes 
Modification Reduces Risk  Yes 
Standardized Measure  No 
  Biological Variability Low 
  Analytical Reproducibility Fair 
Adapted from (Harris and Von Schacky, 2004).  
 
 
In this thesis, a battery of analyses was completed including fatty acid 
composition determinations in plasma, erythrocytes and whole blood.  A novel finger-tip 
prick method was also implemented using whole blood and chromatography strips (see 
Chapter 4 Methods for details).  We further compare multiple blood biomarkers and their 
consistency across these blood fractions in an attempt to provide support for the use of 
one standardized measure for omega-3 blood biomarker analysis that reflects omega-3 
fatty acid intake and health risks/benefits. 
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3.1.2 Previous Omega-3 Fatty Acid Supplementation and Washout Studies 
Supplementation and washout studies are important for future research on the 
physiological effects of omega-3 fatty acids.  Many biological variables have 
considerable inter-individual variation, which require a double-blind, placebo-control 
cross-over design.  It is important to know how long it takes for omega-3 fatty acids to 
accumulate and plateau in tissues as well as how long it is required for omega-3 fatty acid 
levels to return to pre-supplementation levels. 
Blood fractions and lipid classes measured, fish oil dose, and washout and 
supplementation periods vary in previous studies.  Previous washout studies include: a 
high dose of omega-3 fatty acids (5 g per day of EPA + DHA) examining erythrocytes 
only (Brown, Pang, and Roberts, 1991), and a high dose of omega-3 fatty acids (11.3 g 
per day of EPA + DHA) examining phospholipids, TAGs and cholesteryl esters of 
plasma (Zuijdgeest-van Leeuwen et al., 1999).  These studies analyzed fatty acid 
responses to supplementation and washout in one blood fraction only.  Previous studies 
including lower omega-3 doses (from 2.5 to 3.5 g per day EPA + DHA) in plasma and 
erythrocyte phospholipids with different individual phospholipid type compositions 
(Prisco et al., 1996), total lipid extracts of plasma and erythrocytes (Sanders and Hinds, 
1992) and in plasma, erythrocytes, platelets and monocytes (Marangoni et al., 1993) have 
been performed.  These studies are more comprehensive with respect to the number of 
blood fractions measured; however, none of these studies included whole blood fatty acid 
analysis to compare to other fractions.  Furthermore, these studies are performed 
exclusively in males, and when females were included, gender differences were not 
analyzed. 
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In the present study, washout and supplementation was administered to 
individuals, and fatty acid responses were measured comprehensively in plasma, whole 
blood, erythrocytes and finger-tip prick blood (FTPB).  In addition, this study included 
both males and females based on recent literature suggesting enhanced DHA biosynthesis 
and/or mobilization in females (Burdge and Wootton, 2002; Pawlosky et al., 2003a; Stark 
et al., 2005).  
 
3.2 Objectives 
Practical information on the ideal therapeutic approach for omega-3 fatty acid 
supplementation therapy is limited.   This is complicated by a lack of consensus on the 
ideal biomarker to identify omega-3 fatty acids.  Therefore, in this study we wish to 
determine a standard measure for changes in omega-3 levels by determining an omega-3 
blood biomarker that is most accurate and consistent across blood fractions in response to 
supplementation and washout.   
The current study has been designed to determine differences in the responses 
between plasma, whole blood and erythrocyte blood fractions during 4 weeks of 
supplementation and a subsequent 8 weeks of washout.  To our knowledge no previous 
study has compared all three blood fractions of plasma, whole blood and erythrocytes and 
comparisons between male and female responses to fish oil supplementation have not 
been completed.  We also evaluate a rapid and efficient method for the determination of 
omega-3 fatty acids from FTPB samples.  This method is less invasive than venous 
puncture techniques and does not require a trained technician for sample collection.  This 
could potentially allow for the method to be used in field and clinical studies and allow 
for weekly blood collections when weekly venous blood collections may not be possible. 
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3.3 Hypotheses 
1.  DHA levels of young adult females will be higher than those in males at study entry in 
the present population sample (low fish consumers). 
 
2.  Omega-3 fatty acid levels in all blood fractions will increase with omega-3 fatty acid 
capsule supplementation and decrease during the washout, although the incorporation and 
subsequent washout will differ between plasma, erythrocytes and whole blood.   
 
3.  Omega-3 supplementation and washout will result in dynamic changes in EPA and 
DHA in all blood fractions, and the response of EPA will be more dynamic than that of 
DHA. 
 
4.  Finger-tip prick blood sampling for the analysis of omega-3 fatty acid composition 





All procedures and protocols in this thesis received clearance from the University 
of Waterloo Human Ethics Committee and all subjects provided informed written consent. 
 
4.1 Participants 
A total of 10 male and 10 female undergraduates were recruited from the 
University of Waterloo, with 9 males (22.4 yrs ± 1.24) and 7 females (22.1 yrs ± 1.77) 
completing all the study requirements.  Participants were screened for a history of 
smoking, disease, use of relevant medication and the consumption of omega-3 containing 
foods including fish.  Individuals with significant health problems and high omega-3 fatty 
acid intakes were excluded from the study.  Documents and materials used for recruiting, 
collecting subject information and providing study guidelines and results to subjects are 
located in Appendix A, B and C. 
 
4.2 Study Design 
The 12-week study consisted of an initial 4 weeks of omega-3 ethyl ester 
supplementation (Ocean Nutrition Canada, Bedford, N.S.) followed by 8 weeks of 
washout (Figure 4).  Supplementation consisted of 8 capsules per day providing 
approximately 3.2 g EPA and 1.6 g DHA each day.  Fatty acid analysis was performed on 
the fish oil capsules by gas chromatography to verify composition (Table 5).  At weeks 0, 
4, 8 and 12, 10 mL of venous blood was collected from participants who had fasted 12 
hours previous for fatty acid composition analyses.  Weight, blood pressure and heart rate 
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were also measured in a fasted state during each visit.  In addition, heart rate and blood 
pressure measure were taken after the participant had been seated quietly for 
approximately five minutes.  During weeks 0 through 12, two FTPB samples were taken 
on the same day each week from the participants for fatty acid composition analysis.  
Upon their first visit, participants were also given a 3-day diet record to complete on two 
weekdays and one weekend day that was to be returned during their visit the following 
week.  Nutrient intakes were determined using ESHA Food Processor SQL v.10.0 
(ESHA Research, Salem, OR, USA). 
 
Figure 4. Omega-3 Supplementation and Washout Study Design 
 
4.3 Blood Collection 
4.3.1 Finger-Tip Prick 
Fingers were sterilized using an alcohol wipe and allowed to dry.  One finger was 
pricked using a disposable Unistik finger prick lancet (Lifescan, Inc., Milipitas, CA, 
USA).  The first drop of blood was wiped away to avoid alcohol contamination of the 
sample.  Small strips of chromatography paper were used to collect the blood.  The strips 




4.3.2 Venous Blood 
Venous blood was drawn by a certified technician.  Ethylenediamine tetraacetic 
acid was added to prevent blood clotting and aliquots of whole blood were collected and 
frozen at -80˚C for later analysis.  The remaining whole blood was centrifuged at 3000 
revolutions per minute for 15 minutes to separate plasma and erythrocyte fractions.  The 
plasma was removed and aliquots were frozen for later analysis.  Erythrocytes were 
washed twice with saline solution to remove plasma before freezing at -80˚C for later 
analysis. 
Table 5. Composition of a Single Fish Oil Capsule 
Fatty Acid 




16:0 1.66 ± 0.87 0.23 ± 0.12 
18:0 2.90 ± 0.80 0.40 ± 0.11 
18:1n-9 3.34 ± 0.31 0.46 ± 0.04 
18:1n-7 1.21 ± 0.12 0.17 ± 0.02 
20:1n-9 3.31 ± 0.07 0.46 ± 0.01 
20:4n-6 2.01 ± 0.03 0.28 ± 0.01 
20:5n-3 42.42 ± 0.97 5.90 ± 0.16 
23:0 2.19 ± 0.33 0.30 ± 0.04 
22:5n-3 4.84 ± 0.09 0.67 ± 0.02 
22:6n-3 22.01 ± 0.42 3.06 ± 0.07 
Others ~ 14.11 ~ 0.87 
Means ± S.D. 
 
 
4.4 Fatty Acid Analysis  
4.4.1 Preparation of Venous Blood Samples 
Samples were thawed and 22:3n-3 was added as an internal standard for 
quantification of individual fatty acids.  For plasma and whole blood, lipids were 
extracted by the Folch method (Folch, Lees, and Stanley, 1957) while erythrocytes were 
extracted by the method of Reed et al. (Reed et al., 1960) that uses cold methanol with 
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butylated hydroxytoluene (Sigma-Alldrich, St. Louis, MO, USA) to lyse erythrocyte 
membranes before extraction with organic/aqueous solvents (Bligh and Dyer, 1959).  
Fatty acid methyl esters (FAMEs) were methylated using 14% boron trifluoride (BF3) in 
methanol (Alltech, State College, PA, USA) with hexane on a block heater at 95ºC for 60 
minutes (Morrison and Smith, 1964).  The organic phase containing the FAMEs was 
collected and stored at -80ºC until analyzed by gas chromatography. 
 
4.4.2 Preparation of Finger- Tip Prick Samples 
Whole FTPB was collected on thin strips of chromatography paper (Marangoni, 
Colombo, and Galli, 2004) and directly methylated (Kang and Wang, 2005) in 14% BF3 
in methanol in the presence of hexane using a standard microwave (Banerjee, Dawson, 
and Dasgupta, 1992) for 45 seconds of methylation.  An internal standard was not added 
to the finger-tip prick samples as the blood volume of the finger-tip prick sample could 
not be determined.  Therefore the results of this method after gas chromatography 
analysis are qualitative in nature using percent by weight of each fatty acid to total fatty 
acids.  
 
4.5 Analysis of Fatty Acid Methyl Esters by Gas Chromatography 
A Shimadzu GC-17A gas chromatograph equipped with a Shimadzu AOC-17 
autosampler was equipped with a DB-FFAP 30m x 0.25 mm i.d. x mm film thickness, 
nitroterephthalic acid modified, polyethylene glycol, capillary column (J&W Scientific 
from Agilent Technologies, Mississauga, ON).  Hydrogen was used as the carrier gas at a 
pressure 102.4 kPa and a linear velocity of 60 m/s.  FAME samples (2μL) were 
introduced into the autoinjector at a split ratio of 8:1.  The flame ionization detector 
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temperature was 250ºC.  Initial temperature was 130ºC with a 1 min hold followed by a 
4ºC/min ramp to 178ºC, a 1ºC/min ramp to 195ºC with a 17 min hold and then a 
40ºC/min ramp up to 245ºC with a 20 min hold at the end.  A complete run requires 68 
minutes, with a cool-down period and a 1-minute re-equilibration period between sample 
injections (Salem, Jr., Reyzer, and Karanian, 1996). 
 
4.6 Blood Lipid Analysis 
Total cholesterol, HDL cholesterol, TAG and glucose were analyzed on a 
Synchron CX DELTA automated sample processor (Beckman Coulter Inc., Fullerton, 
CA) with the appropriate reagent systems.  LDL cholesterol was determined using the 
proper equation (Friedewald, Levy, and Fredrickson, 1972).  All blood lipid analysis was 
determined in the plasma blood fraction. 
 
4.7 Statistical Analysis 
Statistical analyses were performed with the SPSS System (SPSS Inc., Chicago, 
IL).  A repeated measure Linear Mixed Model analysis was used to determine significant 
differences for each blood fraction (plasma, erythrocytes, whole blood and FTPB).  The 
same model was implemented for lipoprotein and glucose responses in plasma.  An 
interaction effect (gender x time) and main effects of gender and time were determined 
for individual fatty acids.  A one-way ANOVA was used to determine differences 
between blood fractions in n-3 HUFA Score and Omega-3 Index, baseline gender 
differences, venous blood fraction differences and FTPB and whole blood differences. 
Post hoc analyses of individual means were completed by the Bonferroni procedure 





5.1 Participant Characteristics 
5.1.1 Anthropometric Measurements 
Baseline anthropometric values for males and females were determined (Table 6).  
No statistically significant baseline differences (p>0.05) are seen between genders for 
age, resting heart rate or resting diastolic and systolic blood pressure by independent t-
test.  Significant baseline gender differences are seen for height and weight by t-test. 






Age (yrs) 22.4 ± 1.2 22.1 ± 1.8 
Height (cm) 183.6 ± 5.2 171.4 ± 7.1* 
Weight (kg) 90.1 ± 8.8 69.9 ± 14.0* 
Resting HR (bpm) 63.6 ± 6.8 70.3 ± 7.6 
Resting SBP (mmHg) 120.6 ± 9.5 112.9 ± 7.6 
Resting DBP (mmHg) 72.2 ± 7.1 70.7 ± 5.3 
Means ± SD.  HR, heart rate; SBP, systolic blood pressure;  
DBP, diastolic blood pressure. * Significantly different by independent  
t-test (p < 0.05). 
 
 
5.1.2 Dietary Intakes 
 Dietary intakes were determined from 3-day dietary records (Table 7).  Fat, 
protein and energy intakes were all statistically higher in males while there were no 
differences in carbohydrate intake.  Fatty acid subclasses were all higher in males, 
however significant differences were not detected for total polyunsaturates and omega-3 
and omega-6 polyunsaturates as a result of high variance. 
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Table 7. Daily Diet Intakes as Determined by 3-Day Diet Records 
Dietary Intake Males  Females 
Proteins (g) 121 ± 29 68 ± 25* 
Carbohydrates (g) 317 ± 55 268 ± 70 
Total Fats (g) 100 ± 29 46 ± 13* 
Saturated Fatty Acids (g) 37 ± 14 15 ± 6* 
Monunsaturated Fatty Acids (g) 19 ± 9 9.5 ± 4.1* 
Polyunsaturated Fatty Acids (g) 8.3 ± 5.9 4.8 ± 2.7 
   Omega-3 PUFAs (g) 0.78 ± 0.74 0.37 ± 0.23 
   Omega-6 PUFAs (g) 6.3 ± 5.1 3.9 ± 2.4 
Energy (kilocalories) 2704 ± 510 1779 ± 514* 
Mean ± S.D. *Statistically lower than males by independent t-test (p < 0.05) 
 
 
5.1.3 Fasting Blood Lipoprotein, Triacylglycerols and Glucose 
Plasma total cholesterol, TAG, HDL cholesterol, LDL cholesterol and blood 
glucose were measured in venous blood samples (Table 8).  Total cholesterol and HDL 
cholesterol levels are higher (p<0.05 and p<0.001, respectively) in females than males 
throughout the study.  Omega-3 fatty acid supplementation in females lowered (p<0.05) 
TAGs in plasma.  TAG levels did not fully return to baseline for females during washout.  
Male TAGs did not differ with supplementation, but increased during washout.   Baseline 
male TAGs were lower than female baseline TAGs (p<0.05 by paired t-test).  TAGs are 
significantly lower at week 4 compared to baseline in females only by t-test (p<0.05), but 
this failed to reach significance when weeks 8 and 12 were included in the analysis 
(p>0.05 by Linear Mixed Model).  LDL cholesterol is significantly higher during week 
12 compared to week 0 by t-test (p<0.05), however, this too failed to reach significance 
with the inclusion of weeks 4 and 8 (p>0.05 by Mixed Linear Model).  In addition, there 
is a main effect (p < 0.05) of gender with males displaying a higher systolic blood 
pressure and a lower heart rate throughout the course of the study.  There is no effect of 
fish oil supplementation on diastolic blood pressure. 
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Table 8. Plasma Lipid, Lipoprotein, Glucose and Cardiovascular Responses During 
Supplementation and Washout 
Measure Gender Week 0 Week 4 Week 8 Week 12 
  millimoles per litre 
Cholesterol* Male 3.57 ± 0.22 3.62 ± 0.52 3.66 ± 0.48 3.96 ± 0.55 
 Female 4.02 ± 0.83 3.87 ± 0.60 4.11 ± 0.53 4.16 ± 0.57 
 All 3.75 ± 0.57 3.73 ± 0.55 3.86 ± 0.54 4.05 ± 0.55 
      
Triacylglycerols# Male 0.86 ± 0.49 0.82 ± 0.45 1.06 ± 0.34 1.12 ± 0.14 
 Female 1.27 ± 0.40a 0.78 ± 0.33b 1.05 ± 0.34c 1.17 ± 0.55c 
 All 1.02 ± 0.48 0.80 ± 0.39 1.06 ± 0.33 1.14 ± 0.50 
      
HDL Cholesterol* Male 1.01 ± 0.22 0.95 ± 0.10 0.87 ± 0.10 0.93 ± 0.14 
 Female 1.23 ± 0.34 1.26 ± 0.37 1.21 ± 0.31 1.20 ± 0.29 
 All 1.10 ± 0.29 1.08 ± 0.29 1.02 ± 0.27 1.05 ± 0.25 
      
LDL Cholesterol Male 2.17 ± 0.28 2.30 ± 0.40 2.32 ± 0.42 2.53 ± 0.34 
 Female 2.21 ± 0.74 2.26 ± 0.65 2.40 ± 0.67 2.44 ± 0.60 
 All 2.19 ± 0.49a 2.29 ± 0.50ab 2.35 ± 0.53ab 2.49 ± 0.46b 
      
Blood Glucose Male 4.44 ± 0.42 4.48 ± 0.45 4.48 ± 0.29 4.48 ± 0.23 
 Female 4.23 ± 0.22 4.25 ± 0.27 4.41 ± 0.30 4.41 ± 0.24 
 All 4.36 ± 0.36 4.38 ± 0.39 4.45 ± 0.30 4.45 ± 0.23 
  millilitres of mercury 
Systolic BP* Male 120.6 ± 9.5 121.1 ± 4.9 117.8 ± 5.7 121.0 ± 6.6 
 Female 112.9 ± 7.6 112.1 ± 6.4 117.9 ± 12.9 113.8 ± 9.5 
 All 117.2 ± 9.3 117.2 ± 7.1 117.8 ± 9.1 118.6 ± 8.1 
      
Diastolic BP Male 72.2 ± 7.1 75.6 ± 5.8 77.8 ± 6.7 76.6 ± 4.4 
 Female 70.7 ± 5.3 74.3 ± 5.3 75.0 ± 10.0 73.8 ± 7.5 
 All 71.6 ± 6.3 75.0 ± 5.5 76.6 ± 8.1 75.7 ± 5.5 
  beats per minute 
Heart Rate* Male 63.6 ± 6.8 65.7 ± 9.8 61.3 ± 8.7 60.0 ± 8.8 
 Female 70.3 ± 7.6 66.9 ± 8.2 68.0 ± 6.5 67.0 ± 9.5 
 All 66.7 ± 7.8 66.3 ± 8.7 64.3 ± 8.3 62.3 ± 9.3 
Means ± S.D. Analyzed by Mixed Linear Model Repeated Measures ANOVA with p < 
0.05 accepted as significantly different. * Significant main effect of gender. # Significant 
gender difference at week 0 by paired t-test (p < 0.05). Superscripts not sharing the same 
letter are significantly different by paired t-test (p < 0.05). HDL, high-density lipoprotein; 
LDL, low-density lipoproteins.  
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5.2 Blood Fatty Acid Compositions 
5.2.1 Venous Plasma Fatty Acids 
Changes in the fatty acid composition of plasma total lipids are summarized in Table 9.  
SFA were not affected by omega-3 supplementation and washout (p>0.05).  MUFAs, 
however, did decrease in response to omega-3 supplementation and then recovered 
during washout (p<0.01).  These changes were largely due to changes in 18:1n-9 (the 
major MUFA in human tissue, p<0.001). 
Overall, omega-6 PUFA composition in plasma appears to decrease during the 
supplementation period, with a subsequent increase back to baseline during the omega-3 
washout period.  This change, however, is not significant (p=0.070).  Only the decrease 
and recovery of di-homo-γ-linoleic acid (20:3n-6) and adrenic acid (22:4n-6) during 
omega-3 supplementation and washout reached significance (p<0.05). 
As expected, supplementation increased EPA (20:5n-3) in plasma at week 4 
(p<0.001).  The increase did not persist during washout as there were no differences in 
EPA levels at weeks 0, 8 and 12.  Docosapentaenoic acid n-3 (DPAn-3, 22:5n-3) was not 
a major component of the fish oil capsules (Table 4), however, DPAn-3 increased 
(p<0.05) during supplementation, and subsequently decreased (p<0.001) to baseline 
values immediately during washout.  DHA levels increased with supplementation 
(p<0.001) however DHA remained significantly higher than baseline levels at week 8 






Table 9.  Changes in Plasma Fatty Acid Composition with Supplementation and Washout 
Name Week 0 Week 4 Week 8 Week 12 
 weight percent of total fatty acids 
12:0 0.13 ± 0.11 0.09 ± 0.04 0.11 ± 0.05 0.13 ± 0.09 
14:0 1.02 ± 0.29 0.85 ± 0.30 0.92 ± 0.20 0.94 ± 0.37 
16:02 22.5 ± 1.7 21.9 ± 1.7 21.2 ± 5.2 22.1 ± 2.2 
18:0 6.37 ± 0.80 6.79 ± 0.92 6.41 ± 0.84 6.56 ± 1.01 
20:0 0.13 ± 0.02 0.15 ± 0.04 0.12 ± 0.02 0.12 ± 0.02 
22:0 0.32 ± 0.07 0.35 ± 0.12 0.29 ± 0.06 0.30 ± 0.09 
23:0 0.11 ± 0.03 0.15 ± 0.1 0.09 ± 0.04 0.10 ± 0.02 
24:0 0.27 ± 0.07 0.29 ± 0.11 0.25 ± 0.05 0.28 ± 0.17 
SFA2 31.2 ± 1.7 31.2 ± 1.6 31.4 ± 2.4 31.3 ± 2.5 
     
14:1 0.05 ± 0.03 0.04 ± 0.04 0.06 ± 0.08 0.04 ± 0.04 
16:1n-72 2.50 ± 0.94 1.82 ± 0.51 2.04 ± 0.95 2.10 ± 0.66 
18:1n-91 20.8 ± 3.0 a 17.6 ± 2.2 b 20.7 ± 1.9 a 20.8 ± 1.7 a 
18:1n-7 2.00 ± 0.31 1.74 ± 0.24 1.89 ± 0.22 2.00 ± 0.30 
20:1n-92 0.18 ± 0.06 0.17 ± 0.07 0.19 ± 0.04 0.18 ± 0.04 
24:1n-92 0.44 ± 0.10 0.46 ± 0.14 0.36 ± 0.10 0.39 ± 0.19 
MUFA1 26.0 ± 3.5 a 21.4 ± 2.1 b 25.3 ± 2.0 a 25.6 ± 1.9 a 
     
18:2n-6 28.4 ± 3.7 27.3 ± 3.2 29.7 ± 2.8 29.2 ± 3.5 
18:3n-62 0.32 ± 0.09 0.19 ± 0.07 0.33 ± 0.13 0.30 ± 0.10 
20:3n-61 1.46 ± 0.41 a 0.98 ± 0.25 b 1.48 ± 0.37 a 1.57 ± 0.38 a 
20:4n-6 5.91 ± 1.03 5.69 ± 1.04 5.28 ± 1.10 5.78 ± 1.05 
22:4n-61 0.20 ± 0.04 a 0.09 ± 0.05 b 0.16 ± 0.04 a 0.21 ± 0.14 a 
22:5n-6 0.18 ± 0.06 0.10 ± 0.06 0.13 ± 0.04 0.18 ± 0.07 
n-6 PUFA2 36.7 ± 3.7 34.6 ± 3.1 37.3 ± 2.4 37.5 ± 3.3 
     
18:3n-3 0.56 ± 0.10 0.56 ± 0.19 0.56 ± 0.13 0.57 ± 0.21 
20:5n-3(EPA)1 0.35 ± 0.11 a 4.38 ± 1.41 b 0.44 ± 0.14 a 0.38 ± 0.13 a 
22:5n-3 (DPAn-3)1 0.37 ± 0.09 a 0.96 ± 0.19 b 0.40 ± 0.08 a 0.43 ± 0.18 a 
22:6n-3 (DHA)1,2 1.18 ± 0.28 a 3.07 ± 0.63 b 1.47 ± 0.27 c 1.42 ± 0.41 ac 
n-3 PUFA1 2.47 ± 0.35 a 9.27 ± 1.76 b 2.88 ± 0.33 c 2.81 ± 0.52 ac 
Total PUFA1,2 39.2 ± 3.7 a 43.9 ± 2.4 b 40.1 ± 2.5 a 40.3 ± 3.2 a 
     
n-3 HUFA Score1,2 19.8 ± 2.3 a 55.1 ± 5.9 b 24.9 ± 2.4 c 22.4 ± 2.9 c 
EPA+DHA1 1.53 ± 0.32 a 7.75 ± 1.67 b 1.91 ± 0.31 c 1.80 ± 0.41 ac 
DHA:EPA3 3.63 ± 1.42 a 0.76 ± 0.25 b 3.60 ± 1.13 a 4.57 ± 3.78 a 
DHA:DPAn-33 3.48 ± 1.57 ab 3.20 ± 0.41 a 3.81 ± 1.17 b 4.19 ± 3.86 ab 
Means ± S.D. Analyzed by Mixed Linear Model Repeated Measures ANOVA with p < 
0.05 accepted as significantly different 1Significant main effect of time. 2 Significant main 
effect of gender. 3 Significant gender × time interaction. Values in a row not sharing a letter 
superscript are significantly different by Bonferroni’s Post-Hoc test., SFA, saturated fatty 
acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; HUFA, highly 
unsaturated fatty acid; n-3 HUFA Score, % of n-3 HUFA in total HUFA. 
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5.2.2 Venous Erythrocyte Fatty Acids 
 In erythrocytes, there were no significant changes in total SFAs, total MUFAs, 
and total PUFAs, but there were significant changes in n-6 PUFA and n-3 PUFA (Table 
10).  EPA, DPAn-3 and DHA and total n-3 PUFA all increased while LA (18:2n-6) and 
AA (20:4n-6) and total n-6 PUFA decreased after 4 weeks of omega-3 supplementation.  
During washout, EPA, DPAn-3 and DHA all decrease with washout, but only DHA 
remains significantly higher than baseline levels.  LA does return to baseline levels at 
week 12 while AA at 12 weeks does not differ from either baseline or 4 weeks.  Total n-6 
PUFA remains significantly lower at 12 weeks than baseline, possibly because minor 
reductions in other n-6 PUFAs including 22:4n-6 and 22:5n-6. 
5.2.3 Venous Whole Blood Fatty Acids 
Whole blood fatty acid composition is a reflection on the combination of plasma 
and erythrocyte fatty acid compositions (Table 11).  No differences were observed for 
SFA but the rise and fall of MUFAs, particularly 18:1n-9 that occurred in plasma is 
observable in whole blood.  In whole blood, n-6 PUFAs decrease at 4 weeks but increase 
and remain at baseline levels by week 8 and 12 and this effect is largely dictated by 
18:2n-6 and 20:3n-6.  The levels of AA in whole blood were not different at any time 
point.  The n-3 PUFAs significantly increase after 4 weeks of omega-3 supplementation 
and decrease significantly but do not return fully to baseline levels.  This pattern is 
identical for EPA, DPAn-3 and DHA.   
5.2.4 Finger-Tip Prick Blood Fatty Acids 
Finger-tip prick blood (FTPB) was collected weekly and the changes in fatty acid 
composition (Appendix D) partially reflect the changes observed in whole blood.  SFAs  
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Table 10. Changes in Erythrocyte Fatty Acid Composition with Supplementation and Washout 
Name Week 0 Week 4 Week 8 Week 12 
 weight percent of total fatty acids 
12:0 0.07 ± 0.04 0.08 ± 0.03 0.07 ± 0.02 0.06 ± 0.01 
14:0 0.68 ± 0.15 0.69 ± 0.16 0.66 ± 0.13 0.58 ± 0.14 
16:0 22.8 ± 1.4 23.7 ± 1.9 24.3 ± 1.7 24.3 ± 2.3 
18:0 13.2 ± 0.9 13.3 ± 1.2 13.6 ± 2.2 12.8 ± 1.4 
20:0 0.26 ± 0.03 0.29 ± 0.04 0.32 ± 0.05 0.28 ± 0.02 
22:0 1.03 ± 0.18 1.13 ± 0.23 1.31 ± 0.30 1.17 ± 0.19 
23:02 0.13 ± 0.05 0.16 ± 0.04 0.19 ± 0.02 0.17 ± 0.02 
24:01 2.80 ± 0.50 a 3.17 ± 0.60 ab 3.77 ± 0.53 b 3.42 ± 0.48 b 
SFA 42.8 ± 1.3 44.3 ± 2.4 45.7 ± 2.9 45.0 ± 1.7 
     
16:1n-7 0.35 ± 0.08 0.38 ± 0.27 0.35 ± 0.04 0.38 ± 0.12 
18:1n-9 12.8 ± 0.6 12.3 ± 0.7 12.6 ± 0.6 13.3 ± 0.9 
18:1n-7 1.47 ± 0.18 1.45 ± 0.16 1.51 ± 0.14 1.51 ± 0.13 
20:1n-9 0.27 ± 0.03 0.25 ± 0.11 0.26 ± 0.02 0.28 ± 0.03 
22:1n-9 0.03 ± 0.03 0.05 ± 0.03 0.04 ± 0.04 0.05 ± 0.03 
24:1n-9 2.73 ± 0.30 2.85 ± 0.34 3.25 ± 0.23 3.02 ± 0.29 
MUFA 17.8 ± 0.7 17.48 ± 1.24 18.2 ± 0.8 18.8 ± 1.1 
     
18:2n-61 9.82 ± 1.03 a 8.20 ± 1.00 b 9.21 ± 1.04 ab 9.84 ± 0.9 a 
20:2n-61 0.23 ± 0.03 a 0.19 ± 0.03 b 0.22 ± 0.05 ab 0.23 ± 0.03 ab 
20:3n-6 1.49 ± 0.4 1.12 ± 0.37 1.14 ± 0.26 1.41 ± 0.22 
20:4n-61 12.2 ± 1.0 a 10.6 ± 1.2 b 10.1 ± 1.0 ab 10.1 ± 1.7 ab 
22:4n-61 3.06 ± 0.42 a 2.74 ± 0.48 ab 2.19 ± 0.37 ab 2.23 ± 0.41 b 
22:5n-63 0.53 ± 0.1 0.41 ± 0.09 0.36 ± 0.06 0.34 ± 0.08 
n-61 27.3 ± 1.2 a 23.2 ± 2.5 b 23.3 ± 1.2 b 24.1 ± 2.0 b 
     
18:3n-3 0.12 ± 0.02 0.09 ± 0.02 0.11 ± 0.02 0.11 ± 0.01 
20:5n-3 (EPA)1 0.35 ± 0.10 a 2.20 ± 0.57 b 0.96 ± 0.20 c 0.69 ± 0.14 c 
22:5n-3 (DPAn-3)1,2 1.79 ± 0.37 a 2.40 ± 0.34 b 2.01 ± 0.26 ab 2.08 ± 0.24 b 
22:6n-3 (DHA)1,2 2.94 ± 0.77 a 3.82 ± 0.79 b 3.72 ± 0.57 ab 3.49 ± 0.48 ab 
n-31 5.20 ± 0.74 a 8.51 ± 1.29 b 6.80 ± 0.89 abc 6.38 ± 0.52c 
Total PUFA 32.5 ± 1.1 31.8 ± 3.1 30.1 ± 2.0 30.5 ± 2.3 
     
n-3 HUFA Score1,2 22.7 ± 2.6 a 36.2 ± 2.9 b 32.6 ± 3.2 ab 31.1 ± 2.7 b 
EPA+DHA1,2 3.29 ± 0.78 a 6.02 ± 1.15 b 4.68 ± 0.70 ab 4.18 ± 0.49 b 
DHA:EPA3 8.99 ± 3.60 1.83 ± 0.54 3.96 ± 0.72 5.29 ± 1.61 
DHA:DPAn-32 1.75 ± 0.70 1.6 ± 0.30 1.87 ± 0.30 1.70 ± 0.33 
Means ± S.D. Analyzed by Mixed Linear Model Repeated Measures ANOVA with p < 0.05 
accepted as significantly different 1Significant main effect of time. 2 Significant main effect  
of gender. 3 Significant gender × time interaction. Values in a row not sharing a letter  
superscript are significantly different by Bonferroni’s Post-Hoc test., SFA, saturated fatty  
acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; HUFA, highly 
reaches baseline levels at 12 weeks.  EPA, DPAn-3 and total n-3 PUFA at 12 weeks 
unsaturated fatty acid; n-3 HUFA Score, % of n-3 HUFA in total HUFA. 
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Table 11. Changes in Whole Blood Fatty Acid Composition with Supplementation and 
Washout 
Name Week 0 Week 4 Week 8 Week 12 
 weight percent of total fatty acids 
12:0 0.10 ± 0.08 0.11 ± 0.10 0.09 ± 0.03 0.09 ± 0.05 
14:0 0.84 ± 0.27 0.71 ± 0.22 0.73 ± 0.14 0.75 ± 0.26 
16:02 22.3 ± 1.7 21.8 ± 1.3 22.2 ± 1.6 21.9 ± 1.8 
18:02 9.77 ± 1.00 10.3 ± 1.2 9.68 ± 0.99 9.68 ± 1.01 
20:0 0.17 ± 0.02 0.20 ± 0.03 0.17 ± 0.03 0.16 ± 0.03 
22:0 0.48 ± 0.09 0.57 ± 0.12 0.48 ± 0.12 0.47 ± 0.12 
23:0 0.09 ± 0.04 0.12 ± 0.03 0.11 ± 0.02 0.10 ± 0.02 
24:01 0.91 ± 0.19 a 1.12 ± 0.23 b 0.92 ± 0.22 a 0.90 ± 0.23 a 
SFA 35.5 ± 1.6 36.4 ± 1.5 35.5 ± 1.6 35.4 ± 2.0 
     
16:1n-71,2 1.70 ± 0.51 a 1.18 ± 0.37 b 1.59 ± 0.59 ab 1.54 ± 0.52 ab 
18:1n-91 18.0 ± 2.2 a 15.5 ± 1.5 b 18.1 ± 1.3 a 18.3 ± 1.7 a 
18:1n-7 1.86 ± 0.27 1.69 ± 0.21 1.75 ± 0.18 1.80 ± 0.23 
20:1n-9 0.28 ± 0.16 0.20 ± 0.05 0.21 ± 0.03 0.23 ± 0.05 
22:1n-9 0.01 ± 0.02 0.02 ± 0.03 0.05 ± 0.02 0.08 ± 0.02 
24:1n-91 1.01 ± 0.19 ab 1.16 ± 0.24 a 0.96 ± 0.24ab 0.92 ± 0.19 b 
MUFA1 23.1 ± 2.5a 20.0 ± 1.7 b 22.8 ± 1.5 a 23.0 ± 2.0 a 
     
18:2n-61 21.9 ± 2.7 ab 20.2 ± 1.9 a 22.8 ± 1.9 b 22.5 ± 2.0 b 
18:3n-61 0.20 ± 0.07 a 0.12 ± 0.04 b 0.22 ± 0.09 a 0.21 ± 0.07 a 
20:2n-61,2 0.22 ± 0.02 a 0.18 ± 0.03 b 0.23 ± 0.04 a 0.24 ± 0.05 a 
20:3n-61 1.52 ± 0.40 a 1.04 ± 0.28 b 1.52 ± 0.39 a 1.59 ± 0.37 a 
20:4n-62 8.86 ± 1.11 8.37 ± 1.15 8.05 ± 1.18 8.21 ± 1.0 
22:4n-61,2 1.31 ± 0.24 a 1.06 ± 0.39 ab 1.04 ± 0.20 b 1.04 ± 0.21 b 
22:5n-61 0.32 ± 0.07 a 0.26 ± 0.04 b 0.25 ± 0.07 ab 0.27 ± 0.06 ab 
n-61 34.3 ± 2.7 a 31.2 ± 1.8 b 34.1 ± 1.5 a 34.1 ± 1.9 a 
     
18:3n-3 0.40 ± 0.09 0.39 ± 0.13 0.40 ± 0.09 0.42 ± 0.13 
20:5n-3 (EPA)1 0.35 ± 0.11 a 3.61 ± 1.16 b 0.61 ± 0.14 c 0.49 ± 0.10 c 
22:5n-3 (DPAn-3)1,2 0.96 ± 0.26 a 1.66 ± 0.25 b 1.19 ± 0.23 c 1.11 ± 0.20 c 
22:6n-3 (DHA)1,2 1.84 ± 0.35 a 3.42 ± 0.50 b 2.41 ± 0.33 c 2.27 ± 0.36 c 
n-31 3.55 ± 0.43 a 9.09 ± 1.65 b 4.61 ± 0.43 c 4.29 ± 0.40 c 
Total PUFA1 37.9 ± 2.7 a 40.3 ± 1.5 b 38.7 ± 1.6 a 38.4 ± 1.9 a 
     
n-3 HUFA Score1,2 20.89 ± 2.2 a 44.6 ± 5.5 b 28.0 ± 2.1 c 25.9 ± 2.1 d 
EPA+DHA1,2 2.19 ± 0.38 a 7.04 ± 1.57 b 3.02 ± 0.34 c 2.8 ± 0.4c 
DHA:EPA3 5.66 ± 2.00 1.03 ± 0.32 4.13 ± 1.03 4.77 ± 1.17 
DHA:DPAn-33 2.12 ± 0.93 2.09 ± 0.35 2.10 ± 0.50 2.11 ± 0.56 
Means ± S.D. Analyzed by Mixed Linear Model Repeated Measures ANOVA with p < 0.05 
accepted as significantly different. 1 Significant main effect of time. 2 Significant main effect  
of gender. 3 Significant gender × time interaction. Values in a row not sharing a letter  
superscript are significantly different by Bonferroni’s Post-Hoc test., SFA, saturated fatty  
acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; HUFA, highly 
unsaturated fatty acid; n-3 HUFA Score, % of n-3 HUFA in total HUFA. 
 38
did not differ throughout the study.  There was a tendency although not statistically 
significant for total MUFAs and 18:1n-9 to decrease during supplementation followed by 
an increase during washout.  Total n-6 PUFA levels, especially 18:2n-6 and 20:3n-6, to a 
lesser extent, tended to decrease but not significantly during supplementation, followed 
by an increase beyond baseline levels at week 7 that persists until the end of washout.  
Although fatty acid compositions from FTPB reflected venous whole blood fatty  
acid compositions there were significant differences.  At baseline, the FTPB as compared 
with venous whole blood was higher in SFA (53.5 ± 8.3 vs. 35.5 ± 1.6, p < 0.05), and 
lower in MUFAs (16.02 ± 3.25 vs. 23.1 ± 2.5, p < 0.05) and total PUFAs (24.6 ± 5.5 vs. 
37.9 ± 2.7).  FTPB samples were prepared by a novel microwave energy methanolysis 
technique (Banerjee, Dawson, and Dasgupta, 1992), while venous whole blood samples 
were prepared utilizing the traditional methanolysis method of convectional heat by a 
block heater. 
Increases in EPA, DPAn-3, DHA and total n-3 PUFA in FTPB are statistically 
significant after one week of omega-3 supplementation (Figure 5).  Total omega-3 
PUFAs increase (p<0.05) after one week of omega-3 supplementation, reach peak levels 
at Week 4 and remain elevated (p<0.05) relative to baseline throughout washout.  
However there is a significant decrease immediately following the cessation of 
supplementation followed by little or no decreases for the remainder of the washout.  
EPA responds rapidly to dietary intake with an immediate increase of 6.6 fold by week 1 
(p<0.05) and continues to increase (p<0.05) until the end of the supplementation period.  
EPA drops rapidly after supplementation ends; from 10.2 fold higher than baseline to 3.3 
fold higher than baseline from week 4 to week 5.  After week 4, EPA decreases slowly 
and remains significantly higher than baseline during washout until week 12.  DPAn-3  
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Figure 5. Changes in Omega-3 Fatty Acids in Finger-Tip Prick Blood with 
Supplementation and Washout.  Differences in individual means were determined by 
Bonferroni’s Post-Hoc test following a significant F-value by a Mixed Linear Model 
Repeated Measures ANOVA; *significantly different from Week 0; #significantly 
different from Week 4.  PUFA, polyunsaturated fatty acid; EPA, eicosapentaenoic acid; 
DPAn-3. docosapentaenoic acid; DHA, docosahexaenoic acid. 
 
 
increases during the four weeks of supplementation to a much lesser extent and remains 
statistically higher until week 8 of the study although washout does not result in a 
significant decrease (p>0.05) in DPAn-3 from week 4.  The increase in DHA after 
omega-3 supplementation is significant at week 1, but is of less magnitude as compared 
with EPA increases (1.3 fold increase).  DHA levels continue to increase until the end of 
supplementation at week 4 (1.8 fold baseline levels).  DHA levels remain elevated 
(p<0.05) for the entire washout period relative to baseline and there is no significant 
decrease (p>0.05) in DHA levels after week 4.   
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5.3 Omega-3 Fatty Acid Blood Biomarkers 
5.3.1 EPA and DHA Responses in Blood Fractions 
In the erythrocyte, increases in EPA (Figure 6a), and DHA (Figure 6b) levels during 
supplementation occur at a much lower level compared to either plasma or whole blood.  
EPA levels in plasma, erythrocytes and whole blood are similar at baseline, but EPA 
levels in plasma increase to significantly higher levels by week 4 as compared to 
erythrocytes.  In regards to DHA levels, the erythrocyte, whole blood and plasma levels 
all differ at baseline from highest to lowest.  Supplementation resulted in plasma DHA 
increasing rapidly while erythrocyte increases were more restrained.  During washout, 
both EPA and DHA rapidly decrease in plasma, while the decreases in the erythrocyte 
DHA are much slower. 
5.3.2 Omega-3 Index vs. n-3 HUFA Score 
The “omega-3 index” as previously described is the sum of the relative 
percentages of EPA and DHA in the total fatty acid pool of erythrocytes (Harris and Von 
Schacky, 2004).  The “n-3 HUFA score” is the percentage of n-3 HUFA in total HUFA.  
EPA + DHA and the n-3 HUFA score are examined in the context of each blood fraction.  
At baseline, the sum of EPA + DHA is more variable across and specific to each blood 
fraction as compared with the n-3 HUFA score (Figure 7).  EPA + DHA values in 
erythrocytes are more than double values in plasma while the erythrocyte n-3 HUFA 
score is only 15% greater than the plasma n-3 HUFA score.  The baseline EPA + DHA 
values ranged from 1.53 ± 0.52 wt. % in plasma to 3.29 ± 0.78 wt. % in erythrocytes 
while the n-3 HUFA score at baseline ranged from 19.8 ± 2.3 % in plasma to 22.7 ± 2.6 
% in erythrocytes. 
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Figure 6.  EPA and DHA Response During Washout and Supplementation in Plasma, 
Whole Blood and Erythrocytes.  Values in a column not sharing a letter are significantly 
different at P < 0.05 by Bonferroni’s Post-Hoc test following a significant F-value 
(P<0.05) by a One-way ANOVA. 
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Figure 7. Comparison of Omega-3 Blood Biomarkers. A. n-3 HUFA Score. B. Sum of 
EPA + DHA between Blood Fractions at Baseline.  Bars not sharing a superscript are 
significantly different at P < 0.05 by Bonferroni’s Post-Hoc test following a significant F-
value (p<0.05) by One-way ANOVA. 
 43
 Both the sum of EPA + DHA and the n-3 HUFA score increased significantly 
with omega-3 supplementation in all blood fractions (Figure 8).  Weekly FTPB 
determinations indicate that both biomarkers increase significantly at week 1 and 
continue to increase until week 4.  The peak values at the end of supplementation ranged 
from 5.29 ± 1.71 wt. % in FTPB to 7.75 ± 1.67 wt. % in plasma for EPA + DHA and 
ranged from 36.2 ± 2.9 % in erythrocytes to 55.1 ± 5.9 % in plasma for the n-3 HUFA 
score. 
EPA + DHA and the n-3 HUFA score decrease during washout.  The decrease 
from week 4 to week 8 is significant for both biomarkers in all blood fractions except 
erythrocytes.  In erythrocytes, the decrease in both biomarkers reaches significance at 
week 12.  In most cases, biomarkers approached but did not return to baseline by week 12 
of the study.  The exception was the sum of EPA + DHA in plasma, which did return to 
baseline.  Weekly FTPB determinations demonstrate that there is a rapid initial decrease 
in both biomarkers with the cessation of supplementation (week 4 to week 5) and then a 
gradual decline towards baseline for the remainder of the washout period. 
 
5.4 Gender Differences in Fatty Acid Profiles 
5.4.1 Baseline Gender Comparisons 
There were several gender differences in baseline fatty acid compositions in the 
various blood fractions (Table 12).  Females as compared with males tended to have 
higher levels of 16:0 and DHA and lower levels of DPAn-3 across blood fractions with 
some exceptions.  The higher levels of 16:0 in erythrocytes and DHA in FTPB were not 
statistically different than male levels.  The higher 16:0 levels in females is offset by the 
levels of 18:0, which are significantly lower than males in whole blood and erythrocytes. 
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Figure 8.  Changes in Omega-3 Blood Biomarkers. A. n-3 HUFA Score.  
B. Sum of EPA + DHA. 
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Table 12. Baseline Gender Fatty Acid Comparisons in Four Blood Fractions 
Name Plasma Whole Blood Erythrocyte Finger-Tip Pricks 
 Males Females Males Females Males Females Males Females 
 weight percent of total fatty acids 
14:0 0.97 ± 0.33 1.10 ± 0.21 0.76 ± 0.27 0.94 ± 0.26 0.63 ± 0.17 0.74 ± 0.07 1.51 ± 0.41 1.62 ± 0.22 
16:0 21.7 ± 1.0 23.7 ± 1.91 21.3 ± 0.6 23.6 ± 1.81 22.3 ± 1.2 23.5 ± 1.2 23.0 ± 1.5 25.3 ± 1.31 
18:0 6.53 ± 0.71 6.12 ± 0.92 10.2 ± 0.8 9.23 ± 1.012 13.6 ± 0.9 12.8 ± 0.62 22.7 ± 7.1 25.7 ± 7.1 
20:0 0.13 ± 0.02 0.12 ± 0.02 0.18 ± 0.02 0.16 ± 0.02 0.25 ± 0.04 0.26 ± 0.02 0.50 ± 0.28 0.74 ± 0.30 
22:0 0.32 ± 0.06 0.31 ± 0.08 0.50 ± 0.11 0.45 ± 0.05 1.06 ± 0.21 1.01 ± 0.13 0.51 ± 0.13 0.44 ± 0.09 
24:0 0.28 ± 0.08 0.25 ± 0.06 0.97 ± 0.23 0.84 ± 0.10 2.78 ± 0.45 2.82 ± 0.55 0.23 ± 0.09 0.16 ± 0.062 
SFAs 30.5 ± 1.3 32.1 ± 1.82 35.3 ± 1.6 35.9 ± 1.7 42.9 ± 1.6 42.7 ± 0.9 51.8 ± 8.5 55.7 ± 7.3 
         
16:1n-7 2.14 ± 0.38 3.03 ± 1.282 1.6 ± 0.40 1.82 ± 0.66 0.32 ± 0.06 0.39 ± 0.09 1.05 ± 0.21 1.23 ± 0.26 
18:1n-9 20.7 ± 3.9 21.0 ± 1.1 17.5 ± 2.8 18.7 ± 0.8 12.8 ± 0.8 12.8 ± 0.4 12.4 ± 3.5 12.4 ± 2.3 
18:1n-7 1.95 ± 0.32 2.09 ± 0.31 1.83 ± 0.31 1.90 ± 0.24 1.45 ± 0.19 1.49 ± 0.16 1.50 ± 0.37 1.51 ± 0.42 
20:1n-9 0.15 ± 0.06 0.21 ± 0.042 0.33 ± 0.20 0.23 ± 0.02 0.26 ± 0.03 0.28 ± 0.03 0.22 ± 0.13 0.19 ± 0.09 
24:1n-9 0.44 ± 0.12 0.42 ± 0.08 1.06 ± 0.19 0.94 ± 0.17 2.66 ± 0.27 2.81 ± 0.31 0.29 ± 0.18 0.14 ± 0.072 
MUFAs 25.4 ± 4.3 26.8 ± 1.8 22.5 ± 3.2 23.8 ± 1.1 17.7 ± 1.0 17.9 ± 0.2 16.3 ± 3.3 15.6 ± 2.9 
         
18:2n-6 29.4 ± 3.7 27.0 ± 3.5 21.7 ± 2.5 22.1 ± 3.2 9.82 ± 0.72 9.83 ± 1.27 13.1 ± 3.1 12.4 ± 3.3 
18:3n-6 0.32 ± 0.08 0.31 ± 0.10 0.20 ± 0.04 0.19 ± 0.10 0.01 ± 0.02 0.01 ± 0.02 0.20 ± 0.18 0.10 ± 0.06 
20:3n-6 1.43 ± 0.39 1.51 ± 0.48 1.62 ± 0.44 1.38 ± 0.32 1.60 ± 0.49 1.36 ± 0.24 1.18 ± 0.50 0.98 ± 0.22 
20:4n-6 6.17 ± 1.06 5.50 ± 0.92 9.22 ± 1.06 8.36 ± 1.06 12.3 ± 1.3 12.0 ± 0.4 6.87 ± 1.43 5.65 ± 1.102 
22:4n-6 0.19 ± 0.03 0.21 ± 0.06 1.42 ± 0.15 1.16 ± 0.271 3.12 ± 0.26 2.99 ± 0.53 1.19 ± 0.32 0.92 ± 0.36 
22:5n-6 0.16 ± 0.07 0.20 ± 0.05 0.33 ± 0.06 0.32 ± 0.09 0.51 ± 0.07 0.54 ± 0.13 0.20 ± 0.05 0.18 ± 0.03 
n-6 PUFA 37.9 ± 4.1 34.9 ± 2.6 34.7 ± 3.0 33.7 ± 2.5 27.6 ± 1.1 27.0 ± 1.12 23.0 ± 5.0 20.7 ± 4.4 
         
18:3n-3 0.57 ± 0.07 0.56 ± 0.14 0.39 ± 0.06 0.41 ± 0.13 0.12 ± 0.01 0.12 ± 0.02 0.29 ± 0.06 0.31 ± 0.09 
20:5n-3 0.39 ± 0.12 0.30 ± 0.09 0.39 ± 0.12 0.30 ± 0.08 0.38 ± 0.11 0.31 ± 0.07 0.35 ± 0.11 0.21 ± 0.051 
22:5n-3 0.42 ± 0.06 0.30 ± 0.081 1.15 ± 0.16 0.72 ± 0.141 2.05 ± 0.28 1.48 ± 0.171 0.93 ± 0.31 0.51 ± 0.121 
22:6n-3 1.07 ± 0.26 1.34 ± 0.242 1.68 ± 0.26 2.06 ± 0.341 2.51 ± 0.61 3.44 ± 0.601 1.16 ± 0.34 1.40 ± 0.43 
n-3 PUFA 2.45 ± 0.37 2.51 ± 0.36 3.60 ± 0.43 3.49 ± 0.45 5.07 ± 0.77 5.35 ± 0.68 2.75 ± 0.65 2.43 ± 0.61 
Total PUFA 40.3 ± 4.1 37.4 ± 2.3 38.3 ± 3.1 37.2 ± 2.1 32.7 ± 1.2 32.4 ± 0.8 25.8 ± 5.6 23.1 ± 4.9 
         
n-3 HUFA Score 19.1 ± 2.1 20.8 ± 2.2 20.3 ± 1.9 21.6 ± 2.4 22.0 ± 2.7 23.6 ± 2.3 20.7 ± 2.5 21.3 ± 2.2 
EPA + DHA 1.46 ± 0.34 1.64 ± 0.29 2.07 ± 0.36 2.36 ± 0.38 2.90 ± 0.69 3.75 ± 0.611 1.51 ± 0.36 1.61 ± 0.45 
DHA:EPA 2.84 ± 0.62 4.82 ± 1.471 4.51 ± 0.92 7.20 ± 2.051 6.82 ± 1.78 11.5 ± 3.31 3.55 ± 1.21 6.87 ± 2.161 
DHA:DPAn-3 2.61 ± 0.71 4.80 ± 1.621 1.48 ± 0.24 2.97 ± 0.801 1.25 ± 0.34 2.35 ± 0.471 1.32 ± 0.39 2.80 ± 0.611 
Means ± S.D. Analyzed by One-way ANOVA with p < 0.05 accepted as significantly different and p < 0.10 accepted as near significantly different. 1 Significant difference 
between genders. 2 Near significant difference between genders. SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; DHA, docosahexaenoic acid/22:6n-3; EPA, 
eicosapentaenoic acid/20:5n-3; DPAn-3, docosapentaenoic acid/22:5n-3; HUFA, highly unsaturated fatty acid; n-3 HUFA Score, % of n-3 HUFA in total HUFA 




DHA is a biosynthetic endpoint for omega-3 fatty acid elongation and 
desaturation (Figure1).  EPA and DPAn-3 are immediate precursors that can be routinely 
measured using conventional techniques.  In addition to lower DPAn-3 levels, females 
also tended to have lower EPA levels, but only significantly different in FTPB samples. 
Ratios of DHA:EPA and DHA:DPAn-3 were determined and statistically 
analyzed for potential insight on DHA biosynthetic differences between males and 
females.  Both ratios were consistently significantly higher across all blood fractions in 
females as compared with males, potentially indicating enhanced DHA biosynthesis in 
females. 
 
5.4.2 Responses to Supplementation and Gender 
 Gender was included as an independent variable in linear mixed model analysis as 
an interactive term with measures over time and as a main effect of gender.  Body mass 
was included as a covariate in the analyses to adjust for the significantly lower body mass 
of females (Table 4).  A significant interaction between gender × time were detected for 
ratio of DHA:EPA in all blood fractions (Figure 9).  Baseline DHA:EPA is significantly 
higher (p < 0.05) in females compared to males.  However, with omega-3 
supplementation the ratios decrease levels that are not different (p>0.05) from each other.  
Washout results in the ratios increasing in both males and females, but did not reach 
original baseline levels in female erythrocytes, whole blood and FTPB fractions.  The 
increase in females appears higher than males, but did not reach statistical significance.  
The ratio of DHA:DPAn-3 responded similarly with the interaction being significant in 
plasma and whole blood only.  The DHA:DPAn-3 ratios do return to baseline levels by 
week 12.  Significant gender × time interactions were also determined for the n-3 HUFA 
 47
 
Figure 9. Changes in the DHA:EPA Ratio with Supplementation and Washout in Males 
and Females.  Bars not sharing a letter superscript are significantly different at P < 0.05 
by Bonferroni’s Post-Hoc test following a significant F-value (p<0.05) by Linear Mixed 
modelling with a significant gender × time interaction.  
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score in FTPB with equivalent male and female n-3 HUFA scores at baseline.  With 
supplementation, the n-3 HUFA score for females increased to a higher level than males 
after one week (42.60 ± 5.03 vs. 34.70 ± 3.98).  The n-3 HUFA score remained higher in 
females than males until week 6 (2 weeks into washout, 33.6 ± 3.4 for females and 30.3 ± 
2.6 for males).  The n-3 HUFA scores remain the same until the end of the study (week 






6.1 Comments on Hypotheses 
 The present study is the first supplementation and washout study designed to 
evaluate the plasma, erythrocyte, whole blood and finger-tip prick blood responses in 
males and females.  For each blood fraction, the fatty acid composition of total lipid 
extracts was determined rather than fatty acids of individual lipid classes such as 
phospholipids.  The fatty acid composition of total lipid extracts is understudied due to 
limitations in interpreting final results; however determining fatty acid composition of 
total lipid extracts is amenable to automated analyses which would be required for fatty 
acid biomarkers to be evaluated as potential chronic disease risk factors.  Isolating 
individual lipid classes is cumbersome and not suitable for automation. 
 
In regards to the original hypotheses: 
1.  DHA levels of young adult females will be higher than those in males at study entry in 
the present population sample (low fish consumers). 
As hypothesized, DHA is higher in females at baseline levels during week 0 for 
all blood fractions except FTPB.  FTPB variability was too high to gain significance.  In 
addition, when weeks 4, 8 and 12 are included in the analysis, DHA remains significantly 
higher than males throughout the course of the study.  Furthermore, an interaction effect 
(time × gender) for the DHA:EPA and DHA:DPAn-3 ratios is present.  At baseline, 
female ratios are generally higher with supplementation removing these differences. 
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2.  Omega-3 fatty acid levels in all blood fractions will increase with omega-3 fatty acid 
capsule supplementation and decrease during the washout, although the incorporation 
and subsequent washout will differ between plasma, erythrocytes and whole blood.   
 DHA, EPA, DPAn-3 and total omega-3 PUFAs increase during fish oil 
supplementation with a subsequent fall in levels during washout for all blood fractions.  
In accordance with the hypothesis, rate of incorporation and washout is dependent on 
blood fraction, with rates being slowest in erythrocytes and fastest in plasma. Whole 
blood and FTPB demonstrate intermediate rates compared to plasma and erythrocytes. 
 
3.  Omega-3 supplementation and washout will result in dynamic changes in EPA and 
DHA in all blood fractions, and the response of EPA will be more dynamic than that of 
DHA. 
 In all four blood fractions, changes in EPA levels appear to occur faster than in 
DHA, however, supplement composition likely plays a part in this. Supplementation 
results in a more rapid increase in EPA after four weeks compared to DHA in plasma, 
erythrocytes and whole blood. Interestingly, FTPB demonstrates that the rapid increase in 
EPA occurs within the first week of supplementation with a subsequent plateau effect for 
the remaining 3 weeks. In contrast, increases in FTPB DHA are more linear during the 
supplementation period.   Washout EPA responses also demonstrate a quicker decline for 
each blood fraction. 
 
4.  Finger-tip prick blood sampling for the analysis of omega-3 fatty acid composition 
will give results similar to venous whole blood sampling.   
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 FTPB sampling is comparable to whole blood sampling, however, limitations 
were discovered.  FTPB n-3 HUFA score responses to omega-3 supplementation and 
washout were similar to whole blood.  However, total SFA levels are higher and MUFA, 
and PUFA levels are lower in FTPB, likely as a result of microwave based methanolysis 
as compared with convectional heat methanolysis, which is discussed later. 
6.2 Gender Affects Fatty Acid Composition 
Many gender differences exist for multiple fatty acids throughout 
supplementation and washout.  First, both plasma and whole blood 16:0 composition is 
higher in females than males, and total plasma SFAs are higher in females than males.  
Also, palmitoleic acid (16:1n-7) is higher in females in plasma and erythrocytes, and 
lignocercic (24:0) in erythrocytes and nervonic acid (24:1n-9) in plasma are lower in 
females.  Estrogen related differences in these fatty acids have been shown previously 
(Stark, Park, and Holub, 2003).  One possible explanation for the higher 16:0 in females 
is the tendency for TAGs to be higher in the female population, particularly at the 
baseline level in this study.  SFAs, and more specifically 16:0 is primarily located in the 
TAG fraction of human blood. 
For all four blood fractions there is an interaction effect for the ratio DHA:EPA.  
In addition, there is also an interaction effect for the DHA:DPAn-3 ratio in plasma and 
FTPB.  In each fraction of blood the female ratio is higher than the males at baseline.  
The supplementation period results in a convergence of the ratios to a point where they 
are no longer different.  The point where they converge is lower than both male and 
female baseline values.  Furthermore, washout results in DHA:EPA beginning to diverge 
back to their original baseline levels, and DHA:DPAn-3 washout does result in a return to 
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baseline values.  These results support evidence that females have a greater ability for 
converting EPA and DPAn-3 to DHA through two elongase steps, a Δ6 desaturase step 
and peroxisomal oxidation (Pawlosky et al., 2003b; Stark et al., 2005), particularly when 
n-3 HUFA intake is low.  
When omega-3 HUFA intake is low the percent of labelled-DPAn-3 utilized for 
synthesis of labelled-DHA is higher in women than in men and when omega-3 HUFA 
intake is high (i.e. fish-based diet), conversion rates are similar between males and 
females (Pawlosky et al., 2003a).  EPA and DHA status has been shown to be altered 
during pregnancy, hormone replacement therapy and with hormonal therapy in 
transsexuals (Giltay et al., 2004).  High circulating estrogen such as that of pregnant 
women is shown to increase DHA levels and decrease EPA levels (Stark et al., 2005).  
Furthermore, it has been proposed that this upregulation is associated with an increase in 
flux through the peroxisomal β-oxidation step (Sprecher, 2000).   
The Δ6 desaturase enzyme is thought to be the rate-limiting step in this pathway, 
however, there are a number of possible areas of metabolic control including the 
translocation of 24:6n-3 and DHA between the peroxisome and endoplasmic reticulum.  
It has been suggested that men may be particularly dependent on the intake of pre-formed 
DHA (Gerster, 1998). In this study we demonstrate that female DHA and EPA levels 
respond the greatest when supplemented with pre-formed DHA and EPA.  Moreover, our 
data shows no gender effect of supplementation and washout on EPA composition, 
indicating the site of upregulation being located downstream of EPA synthesis. 
Furthermore, gender differences are present in DHA and DPAn-3 for all four 
blood fractions.  DHA is higher in women in all blood fractions.  This observation 
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supports the results discussed above, as higher DHA in females suggests that more DHA 
is being formed from its precursors in the pathway compared to males.  Interestingly, 
DPAn-3 composition is lower in females in all blood fractions except for plasma.  Once 
again, this supports the hypothesis that females are better adept to DHA synthesis from 
fatty acid precursors like DPAn-3.  Lower DPAn-3 in females suggests that a greater 
amount of it is being converted to DHA in the biosynthesis pathway compared to males. 
Our gender results support the hypotheses that females have a greater ability for 
the conversion of EPA or DPAn-3 to DHA through the process of peroxisomal β-
oxidation.  However, we cannot rule out increased mobilization of DHA by females as 
compared with males into the circulating bloodstream from other body tissues in the 
present study design. 
6.3 Effect of Supplementation and Washout on Fatty Acid Compositions 
The fatty acid composition of all blood fractions were affected by dietary 
supplementation with a fish oil derived omega-3 concentrate and the subsequent washout.  
Overall all blood fractions demonstrated an increase in EPA and DHA with 
supplementation and a decrease during washout.  The magnitude and duration of these 
increases were specific to each blood fraction and to EPA and DHA. 
6.3.1 Composition Changes in Blood Fractions 
In the present study, plasma omega-3 fatty acids responded with greater increases 
in levels compared to erythrocytes.  This is true for both EPA and DHA (Figure 6).  
MUFAs, particularly 18:1n-9 decreased in response to supplementation in plasma (Table 
9), but did not change in erythrocytes (Table 10).  For instance, plasma 18:1n-9 
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composition decreases during supplementation and increases back to normal during 
washout.  A reduction in plasma MUFAs as a result of omega-3 supplementation has 
been described previously (Marangoni et al., 1993).  It is believed that 18:1n-9 in plasma 
phospholipids, particularly PC, is being replaced by EPA (Subbaiah, Kaufman, and 
Bagdade, 1993; Zuijdgeest-van Leeuwen et al., 1999).  However, there is evidence of no 
effect of omega-3 supplementation on 18:1n-9 levels in plasma PC and plasma PE 
(Prisco et al., 1996).  Alternatively, 18:1n-9 is also a major fatty acid in plasma 
triacylglycerols and omega-3 supplementations has been demonstrated previously to 
reduce fasting triacylglycerols (Stark et al., 2000).  In the present study, plasma fatty acid 
composition was total lipid extract, thus the phospholipids and triacylglycerols 
contributed to 18:1n-9 levels observed. 
Levels of omega-6 fatty acids were more affected in erythrocyte total lipids as 
compared with plasma total lipids by the supplementation and washout protocol.  
Erythrocyte total fatty acid composition is almost entirely dictated by erythrocyte 
phospholipids (Stark and Bazinet, 2005).  Fish oil supplementation has been 
demonstrated to decrease omega-6 fatty acids in plasma phospholipids previously (Stark 
et al., 2000), therefore the lack of changes in the omega-6 fatty acids in plasma is likely 
an effect of fatty acids from triacylglycerols obscuring the EPA and DHA replacement of 
omega-6 fatty acids in plasma phospholipids.  The initial decrease in arachidonic acid 
with supplementation is very slow to increase back to baseline values in erythrocytes and 
has been displayed previously during omega-3 washout in PE AA (Prisco et al., 1996).  It 
is likely that arachidonic acid in the sn-2 position of PE is being replaced relatively 
quickly by DHA, but washout of DHA is slow and dependent on outward PE transbilayer 
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movement.  Reincorporation of AA into the sn-2 position of PE in the inner bilayer is 
therefore slow and almost non-existent in erythrocytes. 
In contrast, 18:2n-6 is not targeted specifically to the sn-2 position of 
phospholipids, but tends to be incorporated into the sn-1 position of phospholipids, 
particularly PC and not PE.  18:2n-6 is also incorporated in significant amounts into 
triacylglycerols.  The decrease in 18:2n-6 with supplementation and the increase washout 
in the erythrocytes is likely a reflection of preferential incorporation into PC over PE 
(Prisco et al., 1996).  As PC tends to be on the outer bilayer, exchange between 
erythrocytes and plasma is much more rapid and influenced by fatty acids in plasma. 
Finally, as expected whole blood and FTPB fatty acid compositions reflected a 
mixture of the fatty acid changes in plasma and erythrocytes.  Plasma makes up 
approximately 50-60% of blood volume with erythrocytes representing over 95% of the 
cellular material.   
 
6.3.2 Changes in EPA and DHA 
The greater incorporation of EPA into erythrocytes compared to DHA could also 
be attributed to EPA being located primarily on the outer membrane in PC and DHA on 
the inner membrane in PE (Cartwright et al., 1985; Popp-Snijders et al., 1984).  In 
erythrocytes, DHA composition increases less than EPA (although both are significantly 
higher after supplementation) and DHA does not significantly decrease during the 
washout period, while EPA composition does decrease significantly.  An outer bilayer 
location of EPA on the erythrocyte membrane supports dynamic changes as there is no 
transbilayer movement necessary for incorporation into erythrocyte from the plasma.  
DHA requires transbilayer movement to be incorporated into the erythrocyte membrane 
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and is incorporated much slower. 
EPA is equal in plasma, erythrocytes and whole blood at baseline (Figure 6).  
After supplementation plasma and erythrocyte EPA levels are significantly different, 
likely reflecting the high proportion of PC in plasma for EPA incorporation.  The 
erythrocyte also contains significant PC, but also has a much higher proportion of PE 
relative to plasma thus EPA does not incorporate into erythrocyte to the same magnitude 
as plasma.  EPA levels also drop rapidly during washout, but again slightly slower in 
erythrocytes than in plasma.  It can be speculated that with washout, the decrease of EPA 
from the membrane is similar to the rate of increase, reflecting the lack of transbilayer 
movement, allowing free exchange of EPA via PC between plasma and the outer 
membrane of the erythrocyte.  This speculation must be tempered by the condition that in 
the present study plasma phospholipids were not directly determined. 
DHA shows a different trend than EPA with respect to its incorporation into the 
membrane of the erythrocytes.  Incorporation of DHA into erythrocytes results in DHA 
being located primarily in PE of the inner membrane (Cartwright et al., 1985; Popp-
Snijders et al., 1984).  Increases therefore tend to occur more quickly than decreases as 
inward transbilayer movement is more rapid than outward movement, which is thought to 
be based on an ATP-dependent inward transport mechanism (Connor et al., 1992).  At 
Week 4, DHA levels have increased significantly, but at Weeks 8 and 12 DHA has not 
decreased significantly.  
DHA incorporation may occur more readily into erythrocytes during 
erythropoiesis as a result of this location primarily in the inner bilayer.  This suggests that 
DHA levels may also be influenced by turnover of erythrocytes in addition to DHA levels 
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in the plasma (Von Schacky, Fischer, and Weber, 1985).  The present results refute the 
hypothesis that DHA is incorporated only during erythropoeisis and that erythrocytes 
could only be representative of dietary manipulation during periods that are greater than 
the lifespan of erythrocytes (~120 days) (Brown, Pang, and Roberts, 1991).  The weekly 
FTPB collections presented herein (Appendix D) suggests a linear increase in DHA with 
increased intake in contrast with the rapid sharp increase in EPA the first week of 
supplementation until the end of supplementation when it drops rapidly.   
In addition to limitations regarding total lipid extract composition as compared 
with phospholipids when determining mechanisms for differences in observed levels, the 
fish oil supplements contained approximately twice as much EPA as compared with 
DHA (Table 5).  Pure preparations of dietary EPA and dietary DHA would be required 
for supplementation studies to directly compare incorporation rates of EPA and DHA.  
The present findings do support the hypothesis of a slower and possibly ATP-
independent mechanism for the transbilayer movement of EPA-containing phospholipids 
(namely PC) and a relatively faster and possibly ATP-dependent mechanism for the 
transbilayer movement of DHA-containing phospholipids (namely PE) to the inner 
bilayer of erythrocytes.  Furthermore, our results suggest a much slower mechanism for 
the outward movement of DHA-containing phospholipids (PE) for exchange with 
plasma. 
6.4 Omega-3 Blood Biomarker Analysis 
Several blood biomarkers of omega-3 fatty acid intake have been proposed.  This 
includes relative percent of EPA + DHA in erythrocytes (Harris and Von Schacky, 2004) 
and in plasma phospholipids (Prisco et al., 1996), the percentage of n-3 HUFA in total 
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HUFA (Stark et al., 2005), EPA/AA ratio (Rupp et al., 2004) and omega-6/omega-3 
ratios (Harris, 2006).  While there is considerable debate regarding these biomarkers, 
comparisons between them are limited.  In this study, EPA + DHA (Omega-3 Index) and 
the % of n-3 HUFA in total HUFA (n-3 HUFA score) are compared as derived from total 
lipid extracts from four blood fractions that are readily available for clinical collection. 
As shown in Figure 7b, the use of EPA + DHA results in specific values for each 
blood fraction and makes comparisons across blood fractions more complicated.  
Erythrocyte EPA + DHA is significantly higher than plasma, whole blood and FTPB 
Omega-3 Index analysis.  The n-3 HUFA score results in much more comparable 
baseline values (Figure 7a).  In animal studies, the n-3 HUFA score in blood has also 
been demonstrated to better correlate with omega-3 levels in tissues including brain, heart 
and liver (Stark and Bazinet, 2005).  A more consistent value across various blood 
fractions would allow for a simplified recommendation to be developed and promoted to 
front line health professionals and the general public in regards to omega-3 levels to 
target for health benefits.  This provides flexibility in analysis as fasting plasma is often 
readily available from lipoprotein screening, and whole blood collection by finger-tip 
prick is less invasive, does not require professional training and can be completed on 
oneself.  In addition, erythrocyte analysis can be particularly difficult as isolated 
erythrocytes require storage at -80 ºC and they behave much more like a solid tissue 
during sample preparation as compared with the more liquid properties of whole blood, 
and plasma.  Liquid sample handling is much more amenable to automation and the 
resulting high throughput analyses. 
Neither the EPA + DHA or the n-3 HUFA score biomarker remained consistent 
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across blood fractions with acute omega-3 supplementation.  Values were significantly 
different for all three venous blood fractions for both the n-3 HUFA score and EPA + 
DHA biomarker with supplementation.  In the future it may be necessary and relevant to 
determine if chronic omega-3 intake (i.e. individuals who regularly consume large 
quantities of fish) demonstrates a consistent n-3 HUFA score across each of these blood 
fractions as it does in a low-intake population.  This could provide further support for the 
use of the n-3 HUFA score as a more appropriate blood biomarker across blood fraction 
for omega-3 status than EPA + DHA.  Initial data has been collected from one subject 
who consumes fish on a regular basis (i.e. > 5 servings per week).  The results obtained 
from this individual warrants further investigation into the consistency of n-3 HUFA 
status versus the EPA + DHA across all four blood fractions.  In plasma, erythrocytes, 
whole blood and FTPB, the n-3 HUFA score is 58.3, 53.7, 54.3 and 59.5 and for EPA + 
DHA is 8.6, 11.6, 9.1 and 9.4, respectively.  Further research in this area of omega-3 
biomarker analysis needs to be performed. 
6.5 Finger-Tip Prick Method 
In the present study a novel FTPB method for fatty acid analysis was utilized.  
This method has the potential to be a faster, cheaper method of analysis suitable for 
human screening (Armstrong, Metherel, and Stark, unpublished).  This method also 
allowed weekly fatty acid composition determinations – a first to our knowledge – to be 
more easily managed compared to conventional fatty acid analysis.  The method is a 
combination of a finger-tip prick blood collection technique (Marangoni, Colombo, and 
Galli, 2004) with a microwave based methanolysis technique (Banerjee, Dawson, and 
Dasgupta, 1992).   
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The FTPB analysis displays changes in omega-3 fatty acid composition that 
would be expected in a supplementation and washout protocol.  Furthermore, the pattern 
of changes mirrors the changes seen in the venous puncture whole blood samples.  This 
provides support for the validity of the FTPB method of analysis, as the supplemented 
fatty acids demonstrate the same response as whole blood fatty acids.   
During the course of the study, it was discovered that microwave methanolysis 
has limitations that were not previously reported.  The baseline FTPB values (Appendix 
D) indicate SFAs are much higher in FTPB, while MUFAs and PUFAs are much lower in 
FTPB than in whole blood.  This trend is consistent throughout the supplementation and 
washout periods at all time points.  These differences appear to be driven by a 
methylation problem in the 18 carbon fatty acids.  Collection of blood by finger-tip prick 
and then methylation by convectional heat on a block heater resulted in fatty acid 
compositions results identical to venous whole blood samples.  In addition extracts of 
phospholipid and triacylglycerol standards were prepared by conventional techniques and 
methanolyzed by standard one-hour convectional heating and the 45-second microwave 
methylation.  All of steps in the procedures are performed exactly the same according to 
the Folch method described in the results section.  Initial results indicate that fatty acid 
concentrations as determined from the phospholipid standard are significantly lower with 
the microwave methylation relative to the heating block methylation.  Differences in fatty 
acids levels from the triacylglycerol standard did not differ significantly with the different 




6.6 Considerations for Future Cross-Over Studies 
An ideal washout period for this specific omega-3 supplementation concentration 
and duration was not known.  It was our goal to determine the proper washout period for 
future cross-over studies in our laboratory.  Ideally, EPA and DHA compositions should 
return to baseline levels before implementing a placebo condition on a participant in a 
cross-over study.  As shown in the results, plasma EPA and DHA are not significantly 
different than baseline levels after eight weeks of washout, however, they remained 
slightly elevated.  In erythrocytes, EPA is significantly higher than baseline values and 
DHA is not significantly higher but does remain elevated at the end of the washout 
period.  Based on these results it appears that the supplemented omega-3 fatty acids did 
not completely return to baseline.  Therefore, under this specific supplementation 
protocol a slightly longer washout period would be necessary for future cross-over 
studies.  Specifically, it is likely that a total of 12 weeks of washout is required after a 4 
week supplementation with a moderately high dose of fish oil (4g of EPA + DHA each 
day) instead of 8 weeks of washout.  In addition, it was not clear from the present study 
that EPA and DHA levels in particular had reached the maximum level with the present 
dose in 4 weeks. 
6.7 Study Limitations 
 It is not possible to conclude that supplementation of these omega-3 fish oil 
capsules alone alters the omega-3 biosynthetic pathway, thereby accounting for the 
decrease in the DHA:EPA ratio.  This decrease is likely partially attributable to a 
decrease in the conversion of EPA to DHA, however, with a 2:1 ratio of EPA to DHA in 
the supplement capsules a large portion of this decrease must be explained by the 
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composition of the fish oil capsules.  This, however, does not impact the observed gender 
differences in the DHA:EPA ratio throughout the supplementation and washout periods.  
In addition, microwave methylation in the FTPB presents a problem with this novel fatty 
acid analysis method.  This problem is related to improper methylation of the 
phospholipid class of lipids, and can be avoided by using the standard heating block 
methylation procedure.  This, however, would be accomplished at the expense of time.  
Finally, problems involving oxidation of erythrocytes were encountered, particularly for 
males during weeks 8 and 12. This resulted in only one data point being obtained for 
males during week 8, and subsequently no statistical analyses could be performed for 
males at this time. 
6.8 Future Directions 
Future studies related to this thesis project may include more supplementation and 
washout protocols.  In particular, omega-3 dose response studies supplementing DHA 
only and EPA only may provide insight into the proposed gender differences in the 
activity within the long chain PUFA biosynthesis pathways.  In addition, stable isotope 
work using [13C]alpha-linolenic acid may be utilized to examine this same biosynthetic 
pathway in conjunction with analysis of enzyme activity within the pathway. 
6.9 Conclusions 
 As a result of omega-3 PUFA supplementation, we demonstrate a number of 
gender differences (1st hypothesis) between males and females throughout the course of 
the study.  Most notably, the interaction effects (gender × time) displayed for the 
DHA:EPA in all blood fraction and DHA:DPAn-3 in plasma and FTPB, which both are 
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examples of differences in the biosynthetic pathways of long chain PUFAs between 
males and females.  Supplementation of omega-3 fish oil capsules resulted in a slower 
omega-3 PUFA incorporation into erythrocytes, and faster incorporation into plasma.  
This is in agreement with the 2nd hypothesis, and is thought to be due to the slow trans 
bilayer movement that is necessary for the incorporation of, in particular, DHA-rich 
phospholipids into the erythrocyte membranes.  In accordance with our 3rd hypothesis, 
the FTPB method of fatty acid analysis shows similar responses to whole blood analysis. 
FTPB is demonstrated to be a useful tool for fatty acid analysis, particularly when time 
constraints exist, when many samples are needed or when trained personnel are not 
available for venous puncture.  Finally, 8 weeks of washout may not be long enough for 
cross-over study designs examining the effects of acute fish oil supplementation at 
moderately high doses. 
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Appendix A 
Study Recruitment Materials 
 
 
Department of Kinesiology 
 
PARTICIPANTS NEEDED FOR RESEARCH ON: 




For more information, or to volunteer please contact: 
Professor Ken Stark, Ph.D. or Adam Metherel 
Department of Kinesiology 
Phone – (519) 888-4567 ext 7873 
Email - info@n3pufa.org 
 
Information can also be obtained http://www.n3pufa.org 
 
This project has been reviewed and received ethics clearance through the Office 
of Research Ethics, University of Waterloo. Waterloo (519) 888-4567 ext. 6005 
 
 
Participants will be asked to provide blood 
samples and consume fish oil or placebo 
capsules for a 4-week period.  
 
Participants will have routine blood sampling 
done four times over a 12 week period.  Each 
session will require 20 minutes.  Finger-prick 
blood samples will be collected weekly and 
will require 5 minutes.   
 
Participants will receive remuneration for their 
time commitment (up to $50). 
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Appendix B 
Participant Information and Consent Materials 
INFORMATION AND CONSENT FORM 
 
Laboratory of Nutritional & Nutraceutical Research 
Department of Kinesiology 
University of Waterloo 
Title of Project: Length of Time Required for Blood Omega-3 Fatty Acid Status to 
Return to Baseline after Fish Oil Supplementation 
Principal Investigator: Ken D. Stark 
University of Waterloo, Department of Kinesiology 
(519) 888-4567 Ext. 7738 
 
Student Investigator: Adam Metherel 
University of Waterloo, Department of Kinesiology 
(519) 888-4567 Ext. 7873 
Online Information: Visit http://www.n3pufa.org or email info@n3pufa.org 
Purpose of Study: 
People who consume high amounts of marine fish such as the Inuit of Greenland have a 
decreased risk for heart disease compared to the North Americans.  Marine fish contain 
significant amounts of omega-3 fatty acids.  Eating omega-3 fatty acids has been shown 
to decrease the amount of fat circulating in the bloodstream, lower resting heart rate and 
prevent fatal heart attacks in several scientific studies.  Canadians in general eat very low 
levels of omega-3 fatty acids. 
You have been asked to take part in a research study looking at the effects of eating 
omega-3 fatty acid and the length of their benefits.  The amount of omega-3 fatty acids 
you eat is reflected by the amount of omega-3 fatty acids in your blood. 
In this study you will be asked to eat omega-3 fatty acid oil capsules.  We will measure 
blood levels of omega-3 fatty acids as they increase.  We will also measure how long it 
takes for the blood levels to return to their original levels after you stop eating the 
capsules.  This study will also compare the determination of omega-3 levels from venous 
blood sampling to a finger-prick collection method. 
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Procedures Involved in this Study: 
As a participant in this study, you will be asked to complete the following: 
1. Complete a 3-day dietary record, a physical exercise survey and a health 
screening form before Day 0. 
2. Fast overnight and then have up to 10 mL of venous blood taken (see details in 
explanation of procedures and risks), and have your height and weight recorded 
on Day 0. 
3. Consume 8, 1 g capsules per day of omega-3 fish oil with meals for 28 days. 
4. Report weekly for finger prick blood sampling. 
5. Fast overnight and then have up to 10 mL of venous blood taken and height and 
weight on Day 28. 
6. Stop consuming capsules, but continue to report for venous blood sampling on 
week 8 and week 12 and continue with weekly finger prick blood sampling until 
week 12. 
7. Allow your blood to be analyzed for cardiovascular disease risk parameters and 
other biochemical markers including fatty acids. 
Further information about each of these tests is presented on the following sheets. 
Time Commitment: 
The maximum time requirement for these tests will be less than 1 hour in the laboratory 
on for days when venous blood samples are collected (Day 0, Day 28, Day 56 and Day 
84).  Finger prick blood sampling will take place weekly (once per week for the 12 weeks 
of the study). 
Personal Benefits of Participation: 
The purpose is to determine how long the effects of eating omega-3 fatty acids last in a 
sample of Canadians.  You will receive education regarding what omega-3 fatty acids 
are, what foods contain them and the potential health benefits of eating omega-3 fatty 
acids.  Information on this study, previous studies and omega-3 fatty acids can be 
obtained at http://www.n3pufa.org.  
We will provide information regarding your personal omega-3 blood status as well as 
your blood lipid profiles including cholesterol in comparison to current health 
recommendations.  You will also be asked to complete 3-day dietary assessments and 
physical activity surveys.  These assessments may help you to monitor your habits and to 
engage in a healthy lifestyle. 
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Explanation of Procedures and Risks: 
Venous blood sampling and finger prick blood sampling will be performed by trained and 
competent laboratory personnel following universal guidelines for handling blood and 
blood products.  
Three-Day Dietary Records and Physical Activity Survey – You will be asked to 
complete a 3-day dietary record and physical activity survey before entering the study.  
Forms and detailed instructions are attached.  This is a detailed list of everything you eat 
for 3 days.  This information will allow us to compare your diet and activities to the 
results of the other tests. 
Encapsulated Oil Consumption – You will be asked to eat 8 one gram oil capsules daily 
for 4 weeks.  It is recommended that the capsules be consumed with meals throughout the 
day (2 with breakfast, 3 with lunch and 3 with supper).  Eating oil capsules may cause 
nausea and loose stools in some participants.  Others may have an increased incidence of 
"burping" and minor stomach discomfort.  Participants who have difficulty swallowing 
pills or capsules may not be able to complete the study. This information will allow us to 
compare your diet and activities to the results of the other tests. 
Venous Blood Sampling – This is similar to blood samples taken by your physician.  
Venous blood will be collected with an 18-21 gauge needle from a vein in your arm and 
will be collected into glass tubes. For each visit approximately 10 mL of blood will be 
collected.  This procedure may result in slight bruising and bleeding.  This can be 
minimized by the application of direct pressure to the point of needle entry into the vein.  
The use of sterile gauze and alcohol swipes minimizes the risk of infection.  Blood lipids 
including cholesterol levels and the amount of omega-3 fatty acids will be determined.  
These results can also be used to determine your risk of heart disease. 
Finger Prick Blood Sampling –This involves a small and sterile needle pricking the finger 
and blood being collected on a small strip of paper.  There is a slight risk of bruising with 
this technique.  The use of sterile gauze and alcohol swipes minimizes the risk of 
infection.  A new method of determining omega-3 fatty acids from finger prick blood 
sampling will be compared to the usual method that requires venous blood samples. 
Stopping the Capsule Ingestion: 
If you experience any of the adverse effects noted above, you can stop consuming the 
capsules and inform the researchers of this. 
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Special Instructions: 
Participants are asked to refrain from eating fish, seafood or omega-3 foods or 
supplements 14 days before or during the study.  Avoid taking new medications during 
the experiment or inform the researchers the drug you will be taking.  Please refrain from 
donating blood or participating in other experiments during this study.  Participants are 
asked to refrain from drinking alcohol in the 24-hour period to fast overnight (water 
allowed) immediately prior to testing.   
Health Screening Form: 
This questionnaire asks some questions about your health status. This information is used 
to guide us with your entry into the study and ensure your suitability for the study. 
Contraindications to participation in this study include any kidney problems, diabetes and 
any cardiovascular diseases including bleeding disorders. 
Changing Your Mind about Participation: 
Your participation is voluntary.  You may withdraw from this study at any time without 
penalty. To do so, indicate this to the researcher or one of the research assistants by 
saying, "I no longer wish to participate in this study". 
Confidentiality: 
To ensure the confidentiality of individuals’ data, each subject will be identified by an 
identification code known only to the principal investigator and his research assistants.  
All data including questionnaires will be entered and blood samples will be stored under 
this code.  Once data have been entered under an anonymous code and the feedback 
provided, the paper records and code sheet will be confidentially shredded.  
Testing will be performed under private conditions where only laboratory personnel are 
present.  No spectators will be allowed during the testing period.  Blood samples will be 
stored at -80ºC in a secure location in the Department of Kinesiology.  After biochemical 
analyses and data interpretation is complete, any remaining blood samples will be 
disposed in compliance with procedures of the Safety Office of the University of 
Waterloo. 
Participant Feedback: 
After the study is completed, you will be provided with a feedback sheet that will include 
your personal measurements and current recommendations based on scientific literature. 
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Compensation: 
You will receive a total of $50 remuneration for completing the study.  Partial payment 
will be provided upon early withdrawal.  The sum will be proportional to the length of 
time and the number of procedures you undertake. This is provided to cover the cost of 
transportation and time commitment of the participant. 
Contact Information: 
If you have any questions about the study at any time, please contact either Professor Ken 
Stark at his/her office (519) 888-4567 ext. 7738, or Adam Metherel at extension 7873, or 
the Lab Assistants at ext. 7873. 
Concerns about Your Participation 
I would like to assure you that this study has been reviewed and received ethics clearance 
through the Office of Research Ethics. However, the final decision about participation is 
yours. If you have any comments or concerns resulting from your participation in this 




I agree to take part in a research study being conducted by Professor. Ken Stark and 
Adam Metherel of the Department of Kinesiology, University of Waterloo. 
I have made this decision based on the information I have read in the Information letter. 
All the procedures, any risks and benefits have been explained to me. I have had the 
opportunity to ask any questions and to receive any additional details I wanted about the 
study. If I have questions later about the study, I can ask one of the researchers Professor 
Ken Stark at his/her office (519) 888-4567 ext. 7738, or Adam Metherel at extension 
7873 in the Department of Kinesiology or by emailing info@n3pufa.org. 
I understand that I may withdraw from the study at any time without penalty by telling 
the researcher.  
This project has been reviewed by, and received ethics clearance through, the Office of 
Research Ethics at the University of Waterloo.  I am aware that I may contact this office 
(888-4567, ext. 6005) if I have any concerns or questions resulting from my involvement 
in this study. 
 
_______________________________ ___________________________________ 
Printed Name of Participant   Signature of Participant 
 
_______________________________ ___________________________________ 
Dated at Waterloo, Ontario   Witnessed 
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CONTACT INFORMATION FOR FINAL RESULTS 
Your results and a brief summary of the results of the trial will be mailed to you unless 
you specify otherwise. 
 
I want to receive the results of the study: Yes ( )   No ( ) 










HEALTH SCREENING FORM 
Study: The Effect of Omega-3 Fatty Acid Supplementation on Heart Rate Dynamics 
 
Name:   
 
Local Address:   
 
Phone #:     Birth Date:  
 





SELF REPORT CHECK LIST 
 
Past Health Problems:  
 
Rheumatic Fever ( )  Epilepsy   ( ) 
Heart Murmur ( )  Varicose Veins  ( ) 
High Blood Pressure ( )  Disease of Arteries  ( ) 
High Cholesterol ( )  Emphysema, Pneumonia, 
Congenital Heart Disease ( )   Asthma, Bronchitis ( ) 
Heart Attack ( )  Back Injuries   ( ) 
Heart Operation ( )  Other (describe overleaf) ( ) 
Diabetes (diet or insulin) ( )  Kidney and liver disease ( ) 
Ulcers ( )  Heartburn   ( ) 
Bleeding from Intestinal Tract ( )  
Enteritis/colitis/diverticulitis ( )   




List current problems:   List medications taken now or in last 3 months: 
 
1.     1. 
 
2.     2. 
 





Irregular Heart Beat ( )  Fatigue  ( ) 
Chest Pain  ( )  Cough Up Blood ( ) 
Short of Breath ( )  Back Pain/Injury ( ) 
Persistent Cough ( )  Leg Pain-Injury ( ) 








Do you use fish oil supplements?    Yes ( )  No ( ) 
Do you use flaxseed oil supplements?   Yes ( )  No ( ) 
Do you consume foods enriched in omega-3 fatty acids? Yes ( )  No ( ) 
 (Examples – Omega Eggs, Milk with Omega-3s) 
Do you take vitamin-mineral supplements regularly? Yes ( )  No ( ) 




How often do you consume fish? 
 Never ( ) Occasionally ( ) Regularly ( )  Often ( ) 
             (1-2 times/mos)          (1-2 times/wk)        (>2 times/wk) 
 
 
Current Physical Activity Status: 
 
I consider my physical activity status to be: High ( ), Average ( ), Low ( ). 











The current study has been identified as requiring medical clearance:    
 
Yes_____  No___X__ 
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COMPLETING THE DIETARY RECORD 
 
• Record all food eaten for 3 days (including one weekend day). 
• Do not alter your intake during the recording period. 
• Record if you are taking a vitamin and mineral supplement. 
• Be sure to include alcoholic beverages and all snack foods. 
• Record what you are eating at the time of the meal and not afterwards. 
• Be sure to include brand names wherever possible. 
• Remember: try to estimate less and measure more. 
• Include what the source of the meal was ie. home cooked, Burger King, etc. in the 
appropriate column. 
 
There is a wrong way and a right way 
  
2 hot dogs 2 enriched white hot dog buns (Wonder® 
brand) 
2 boiled 6” Shopsy’s® all beef wieners 
2 tbsp ketchup 
1 tbsp mustard 
1 glass of milk 1 10 oz. glass of 2% milk 
1 apple 1 apple (diameter 5”) 
1 small salad with ranch dressing 1 small salad 
1/4 head of iceburg lettuce 
1/4 small tomato 
1/2 carrot 
4 tbsp Hidden Valley® ranch dressing 
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DIETARY ANALYSIS INTAKE FORM 
Day 1  
Date:     Name: 
Please Consult your instruction sheets for directions on how to fill out this form 
List of Foods 
No
. 
Amount Detailed Description of Food Source 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
17    
18    
19    
20    
21    
22    
23    
24    
25    
26    
27    
28    
29    
30    
31    
32    
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DIETARY ANALYSIS INTAKE FORM 
Day 2 
Date:     Name: 
Please Consult your instruction sheets for directions on how to fill out this form 
List of Foods 
No
. 
Amount Detailed Description of Food Source 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
17    
18    
19    
20    
21    
22    
23    
24    
25    
26    
27    
28    
29    
30    
31    
32    
 77
DIETARY ANALYSIS INTAKE FORM 
Day 3 
Date:     Name: 
Please Consult your instruction sheets for directions on how to fill out this form 
List of Foods 
No
. 
Amount Detailed Description of Food Source 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
17    
18    
19    
20    
21    
22    
23    
24    
25    
26    
27    
28    
29    
30    
31    
32    
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PHYSICAL ACTIVITY SURVEY 
 
Activities in the Last Year 
Check of months for which the activity was performed and for each activity enter the 
total number of times it was completed. 
 
 
Walking for exercise 
Jogging (using short strides) 
Running (using long strides) 
Bicycling 
 















Swimming at a pool 
























in last  
12 months 



































































Participant Results Materials 






 Day 0 Day 28 Day 56 Day 84 
Total Cholesterol 
(mmol/L)     
LDL Cholesterol 
(mmol/L)     
HDL Cholesterol 
(mmol/L)     
Triglycerides 
(mmol/L)     
Blood Glucose 
(mmol/L)     
% of Omega-3 in 
Blood *     
*Canadian average is 4.5% and 8% may provide cardiovascular benefits. 
 
Height: ________   Weight:  Phase 1(Day 0): ________   (Day 28): ________ 
 
 Phase 2(Day 0): ________   (Day 28): ________ 
 
Current Medical Guidelines: 
 
LDL Cholesterol (mmol/L): Total Cholesterol (mmol/L): 
< 2.60 Optimal < 5.20 Desirable 
2.60-3.37 Near Optimal/Above 
Optimal 
5.20-6.23 Borderline High 
3.38-4.15 Borderline High ≥ 6.24 High 
4.16-4.93 High   
≥ 4.94 Very High HDL Cholesterol (mmol/L): 
  Low < 1.04 
Triglycerides (mmol/L): High ≥ 1.56 
< 1.70 Normal   
1.70-2.25 Borderline High BMI (kg/m2): 
2.26-5.64 High < 20 Underweight 
≥ 5.65 Very High 20-25 Normal 
  25-27 High Normal 
  > 27 Overweight 
 
If you have any concerns, you should consult your physician. 
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Appendix D.  Changes in Finger-Tip Prick Blood Fatty Acid Composition  
Name Week 0 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Week 10 Week 11 Week 12 
 weight percent of total fatty acids 
12:0 0.61 ± 0.30 0.72 ± 0.4 0.60 ± 0.19 0.72 ± 0.29 0.82 ± 0.26 1.50 ± 0.97 1.29 ± 0.41 0.84 ± 0.33 0.76 ± 0.25 1.05 ± 0.26 0.97 ± 0.28 0.87 ± 0.35 0.92 ± 0.29 
14:0 1.56 ± 0.34 1.65 ± 0.44 1.50 ± 0.40 1.41 ± 0.37 1.33 ± 0.24 1.89 ± 0.87 1.83 ± 0.45 1.35 ± 0.40 1.15 ± 0.21 1.33 ± 0.27 1.29 ± 0.26 1.34 ± 0.36 1.29 ± 0.24 
16:0 24.0 ± 1.9 25.4 ± 3.0 24.3 ± 2.0 25.1 ± 2.7 25.2 ± 2.1 26.7 ± 2.3 25.9 ± 2.6 24.4 ± 2.7 25.4 ± 2.5 26.5 ± 2.0 25.8 ± 2.3 25.6 ± 2.9 25.9 ± 2.1 
18:0 24.0 ± 7.3 25.2 ± 8.8 19.6 ± 5.5 23.1 ± 7.5 23.7 ± 5.3 21.6 ± 8.8 22.0 ± 6.3 18.2 ± 4.1 19.2 ± 6.1 21.5 ± 6.2 20.4 ± 8.3 16.5 ± 4.5 20.00 ± 4.8 
20:0 0.61 ± 0.33 0.49 ± 0.21 0.32 ± 0.11 0.4 ± 0.14 0.40 ± 0.11 0.34 ± 0.18 0.36 ± 0.16 0.42 ± 0.36 0.25 ± 0.11 0.29 ± 0.11 0.27 ± 0.14 0.21 ± 0.08 0.25 ± 0.08 
22:0 0.48 ± 0.12 0.57 ± 0.3 0.47 ± 0.15 0.43 ± 0.13 0.33 ± 0.15 0.28 ± 0.13 0.23 ± 0.11 0.23 ± 0.09 0.15 ± 0.03 0.17 ± 0.04 0.17 ± 0.03 0.19 ± 0.06 0.15 ± 0.04 
24:0 0.20 ± 0.09 0.2 ± 0.14 0.17 ± 0.07 0.16 ± 0.07 0.19 ± 0.14 0.14 ± 0.04 0.12 ± 0.07 0.21 ± 0.16 0.14 ± 0.04 0.15 ± 0.06 0.15 ± 0.04 0.20 ± 0.12 0.14 ± 0.04 
SFA 53.5 ± 8.3 56.4 ± 10.8 49.9 ± 6.0 54.0 ± 10.2 53.7 ± 8.0 54.2 ± 11.0 53.4 ± 8.8 47.1 ± 6.0 48.8 ± 7.8 52.8 ± 7.9 50.8 ± 10.4 46.7 ± 6.6 50.6 ± 6.4 
              
14:1 0.02 ± 0.05 0.04 ± 0.1 0.02 ± 0.06 n.d. 0.01 ± 0.04 0.01 ± 0.05 n.d. 0.01 ± 0.05 0.01 ± 0.03 0.01 ± 0.03 0.02 ± 0.04 0.02 ± 0.04 0.01 ± 0.03 
16:1n-7 1.13 ± 0.25 0.82 ± 0.22 0.92 ± 0.22 0.88 ± 0.28 0.90 ± 0.30 1.05 ± 0.61 1.06 ± 0.45 1.14 ± 0.37 1.24 ± 0.51 1.20 ± 0.55 1.1 ± 0.51 1.27 ± 0.45 1.05 ± 0.37 
18:1n-9 12.4 ± 3.2 10.3 ± 2.3 11.5 ± 2.0 10.4 ± 2.5 10.5 ± 2.2 12.0 ± 3.6 11.2 ± 2.5 14.0 ± 1.9# 14.2 ± 2.4# 13.4 ± 2.9 13.1 ± 3.0 14.7 ± 2.0# 14.0 ± 2.3# 
18:1n-7 1.5 ± 0.4 1.28 ± 0.42 1.52 ± 0.32 1.31 ± 0.37 1.36 ± 0.32 1.35 ± 0.44 1.32 ± 0.37 1.58 ± 0.23 1.55 ± 0.24 1.50 ± 0.34 1.49 ± 0.39 1.67 ± 0.32 1.58 ± 0.25 
20:1n-9 0.21 ± 0.12 0.17 ± 0.07 0.2 ± 0.08 0.18 ± 0.11 0.20 ± 0.13 0.14 ± 0.05 0.17 ± 0.11 0.23 ± 0.11 0.15 ± 0.03 0.15 ± 0.04 0.16 ± 0.05 0.18 ± 0.07 0.14 ± 0.03 
24:1n-9 0.22 ± 0.16 0.23 ± 0.14 0.23 ± 0.29 0.16 ± 0.11 0.11 ± 0.10 0.16 ± 0.13 0.11 ± 0.06 0.23 ± 0.19 0.09 ± 0.05 0.1 ± 0.06 0.11 ± 0.05 0.17 ± 0.10 0.08 ± 0.03 
MUFA 16.0 ± 3.3 13.1 ± 2.9 15.7 ± 3.0 13.7 ± 3.3 13.6 ± 2.9 15.0 ± 4.4 14.6 ± 3.2 17.5 ± 2.2# 17.5 ± 3.0 16.6 ± 3.6 16.3 ± 3.8 18.3 ± 2.5# 17.1 ± 2.7# 
              
18:2n-6 12.8 ± 3.2 10.8 ± 3.5 11.3 ± 2.73 10.4 ± 3.2 10.8 ± 2.5 12.3 ± 4.2 12.6 ± 3.3 16.0 ± 3.4# 16.8 ± 2.6# 14.6 ± 3.2 15.5 ± 4.1 17.3 ± 3.5# 15.6 ± 3.1# 
18:3n-6 0.16 ± 0.15 0.08 ± 0.05 0.11 ± 0.12 0.10 ± 0.09 0.11 ± 0.08 0.11 ± 0.09 0.11 ± 0.06 0.13 ± 0.06 0.15 ± 0.08 0.13 ± 0.08 0.11 ± 0.04 0.15 ± 0.08 0.1 ± 0.04 
20:2n-6 0.31 ± 0.34 0.27 ± 0.15 0.54 ± 0.55 0.22 ± 0.16 0.28 ± 0.22 0.35 ± 0.38 0.20 ± 0.13 0.21 ± 0.05 0.17 ± 0.07 0.17 ± 0.03 0.27 ± 0.19 0.41 ± 0.41 0.21 ± 0.17 
20:3n-6 1.09 ± 0.41 0.83 ± 0.3 0.82 ± 0.30 0.90 ± 0.43 0.72 ± 0.22 0.98 ± 0.47 1.04 ± 0.26 1.30 ± 0.40# 1.35 ± 0.44# 1.21 ± 0.41 1.29 ± 0.41# 1.45 ± 0.43# 1.41 ± 0.33# 
20:4n-6 6.34 ± 1.45 6.6 ± 2.6 6.76 ± 1.70 5.73 ± 1.80 5.23 ± 1.34 5.14 ± 1.58 5.66 ± 1.41 6.74 ± 1.46 6.90 ± 1.72 6.02 ± 1.70 6.93 ± 2.00 6.89 ± 1.35 6.81 ± 1.12 
22:4n-6 1.07 ± 0.36 1.11 ± 0.44 1.13 ± 0.36 0.92 ± 0.31 0.86 ± 0.27 0.81 ± 0.31 0.91 ± 0.27 0.97 ± 0.28 1.01 ± 0.29 0.88 ± 0.25 1.04 ± 0.32 1.03 ± 0.29 1.01 ± 0.23 
22:5n-6 0.19 ± 0.05 0.23 ± 0.16 0.25 ± 0.18 0.19 ± 0.11 0.16 ± 0.04 0.16 ± 0.10 0.16 ± 0.07 0.19 ± 0.10 0.17 ± 0.05 0.15 ± 0.06 0.17 ± 0.06 0.17 ± 0.05 0.16 ± 0.04 
n-6 PUFA 22.0 ± 4.9 20.1 ± 6.3 21.0 ± 4.4 18.5 ± 5.2 18.2 ± 4.0 19.8 ± 5.8 20.7 ± 4.6 25.5 ± 4.7# 26.6 ± 4.4# 23.2 ± 4.9 25.3 ± 5.9 27.4 ± 4.6# 25.3 ± 3.7# 
              
18:3n-3 0.3 ± 0.07 0.28 ± 0.09 0.35 ± 0.10 0.26 ± 0.09 0.29 ± 0.10 0.35 ± 0.14 0.34 ± 0.13 0.38 ± 0.15 0.33 ± 0.07 0.31 ± 0.09 0.36 ± 0.14 0.4 ± 0.13 0.34 ± 0.11 
20:5n-3 0.29 ± 0.11 1.92 ± 0.79* 2.32 ± 0.73* 2.71 ± 1.14* 2.96 ± 1.04* 0.95 ± 0.49*# 0.72 ± 0.31*# 0.60 ± 0.12*# 0.53 ± 0.15*# 0.45 ± 0.15# 0.50 ± 0.17*# 0.5 ± 0.12*# 0.41 ± 0.08# 
22:5n-3 0.75 ± 0.33 1.04 ± 0.47* 1.11 ± 0.34* 1.21 ± 0.49* 1.18 ± 0.35* 1.05 ± 0.20 1.03 ± 0.24 1.09 ± 0.30 1.13 ± 0.32 0.98 ± 0.29 1.13 ± 0.35 1.07 ± 0.32 1.01 ± 0.2 
22:6n-3 1.26 ± 0.4 1.7 ± 0.4* 2.02 ± 0.60* 1.90 ± 0.55* 2.32 ± 1.00* 1.97 ± 0.78* 1.88 ± 0.61* 2.22 ± 0.37* 2.02 ± 0.46* 1.78 ± 0.64 1.93 ± 0.57* 1.87 ± 0.39 1.86 ± 0.32 
n-3 PUFA 2.61 ± 0.66 4.93 ± 1.62* 5.80 ± 1.28* 6.08 ± 1.84* 6.82 ± 1.99* 4.33 ± 1.18*# 3.96 ± 0.93*# 4.29 ± 0.74*# 4.02 ± 0.82*# 3.52 ± 1.02*# 3.91 ± 1.00*# 3.85 ± 0.77*# 3.61 ± 0.42*#
Total PUFA 24.6 ± 5.5 25.1 ± 7.8 26.8 ± 5.3 24.6 ± 6.4 25.0 ± 5.6 24.2 ± 6.7 24.6 ± 5.4 29.8 ± 5.4 30.6 ± 5.0 26.7 ± 5.8 29.2 ± 6.7 31.3 ± 5.1 28.9 ± 3.9 
              
DHA:EPA 5.00 ± 2.37 1.01 ± 0.37 0.92 ± 0.26 0.85 ± 0.43 0.82 ± 0.30 2.45 ± 1.08 2.92 ± 1.18 3.76 ± 0.45 3.95 ± 1.01 4.12 ± 1.15 4.01 ± 0.98 3.89 ± 0.9 4.58 ± 0.91 
DHA:DPA 1.97 ± 0.9 1.84 ± 0.6 1.90 ± 0.57 1.67 ± 0.40 1.93 ± 0.40 1.86 ± 0.54 1.84 ± 0.52 2.15 ± 0.56 1.85 ± 0.41 1.86 ± 0.49 1.75 ± 0.46 1.82 ± 0.42 1.92 ± 0.50 
HUFA Score 21.0 ± 2.4 35.0 ± 4.6 38.2 ± 5.9 42.9 ± 7.5 47.8 ± 5.4 35.7 ± 4.6 31.7 ± 3.3 30.1 ± 2.3 28.3 ± 2.5 27.8 ± 2.4 27.4 ± 2.3 26.5 ± 2.1 26.0 ± 2.0 
EPA+DHA 1.55 ± 0.41 3.37 ± 1.46* 4.34 ± 1.15* 4.61 ± 1.46* 5.29 ± 1.71* 2.92 ± 1.01*# 2.59 ± 0.72*# 2.62 ± 0.88*# 2.55 ± 0.54*# 2.23 ± 0.75# 2.42 ± 0.68*# 2.37 ± 0.46*# 2.27 ± 0.35*#
Mean ± S.D. Differences in individual means were determined by Bonferroni’s Post-Hoc test following a significant F-value by a Mixed Linear Model Repeated Measures ANOVA; *significantly 
different from Week 0; #significantly different from Week 4.  SFA, saturated fatty acid; n.d., not detected; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; DHA, 
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